[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1345
1. Gogo-Abite M, Seleye-Fubara D, Jamabo RS: Fibroadenoma coexisting with infiltrating ductal carcinoma--a case report. Niger J Med; 2005 Apr-Jun;14(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenomas are benign breast tumours that are commonly diagnosed in young women in their 20's and early 30's.
  • Occurrence of malignancy in the breasts of these women is very rare.
  • METHOD AND RESULT: We report a case of an infiltrating ductal carcinoma within an otherwise benign fibroadenoma in a 23-year-old woman.
  • She presented with a lump, approximately 7cm in diameter, in her right breast.
  • CONCLUSION: Fibroadenomas are commonly diagnosed in patients in their 20's when the risk of developing breast cancer is extremely rare.
  • Despite this rarity all excised breast lumps should be subjected to histopathological evaluation in order to avoid a diagnostic pitfall.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083250.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


2. Hori T, Taniguchi K, Kurata M, Nakamura K, Kato K, Ogura Y, Iwasaki M, Okamoto S, Yamakado K, Yagi S, Iida T, Kato T, Saito K, Wang L, Kawarada Y, Uemoto S: Carcinoembryonic antigen-producing adrenal adenoma resected using combined lateral and anterior transperitoneal laparoscopic surgery. World J Gastroenterol; 2007 Dec 7;13(45):6094-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorodeoxyglucose positron emission tomography showed increased uptake in the adrenal tumor only, with a maximum standardized uptake value of 2.8.
  • Selective venography and blood sampling revealed that the concentrations of cortisol, catecholamines and CEA were significantly elevated in the vein draining the tumor.
  • A diagnosis of CEA-producing benign adenoma was made.
  • Histopathological examination revealed a benign adenoma.
  • [MeSH-major] Adenoma / blood. Adrenal Gland Neoplasms / blood. Carcinoembryonic Antigen / blood. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023107.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  • [Number-of-references] 11
  • [Other-IDs] NLM/ PMC4250898
  •  go-up   go-down


3. Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ: Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer. Br J Cancer; 2009 Jul 21;101(2):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with benign gastric diseases.
  • Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 x 10(-7)) in the serum of gastric cancer patients relative to individuals with benign gastric disease.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):41-4 [11154168.001]
  • [Cites] Scand J Gastroenterol. 2000 Sep;35(9):950-6 [11063155.001]
  • [Cites] Eur J Clin Invest. 2001 Apr;31(4):337-43 [11298781.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):125-32 [11520595.001]
  • [Cites] Tumour Biol. 2001 Sep-Oct;22(5):318-22 [11553862.001]
  • [Cites] Helicobacter. 2001 Sep;6(3):216-24 [11683924.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1061-6 [11668338.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):298-304 [11919217.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1311-24 [11943716.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):735-9 [12738449.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 2:ii31-6 [12810455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9 [12878730.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6971-83 [14583499.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):139-44 [14693236.001]
  • [Cites] Am J Clin Pathol. 2008 May;129(5):772-9 [18426738.001]
  • [Cites] J Immunol. 2008 Jun 1;180(11):7338-48 [18490733.001]
  • [Cites] Pathol Oncol Res. 2008 Mar;14(1):79-83 [18347935.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R48 [18510725.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:42-7 [15335412.001]
  • [Cites] Oncology. 1999 Jul;57(1):55-62 [10394126.001]
  • [Cites] Gastric Cancer. 2004;7(4):233-9 [15616771.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1485-503 [16285950.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Gut. 2006 Jun;55(6):797-802 [16488898.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Immunity. 2006 Oct;25(4):595-606 [17045821.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Lett. 2008 Mar 18;261(2):147-57 [18171602.001]
  • [Cites] J Exp Med. 1999 Nov 15;190(10):1375-82 [10562313.001]
  • [Cites] Am J Surg. 2001 Jan;181(1):16-9 [11248169.001]
  • (PMID = 19550422.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 2; 0 / human neutrophil peptide 3
  • [Other-IDs] NLM/ PMC2720195
  •  go-up   go-down


Advertisement
4. Elayat G, Selim AG, Wells CA: Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. Ann Diagn Pathol; 2010 Feb;14(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
  • Apocrine metaplasia (APM) is a common finding in the breast of postmenopausal women and is seen in a broad spectrum of lesions ranging from microscopic cysts to invasive apocrine carcinoma.
  • Apocrine metaplasia within sclerosing adenosis is known as apocrine adenosis (AA) and is considered a benign lesion of the breast.
  • The results showed that all cases studied by immunohistochemistry were positive for the expression of Bak, Mcl-1, Bcl-x, and Bcl-x(L) showing a pattern of staining similar to that seen in the normal breast epithelium.
  • There was no statistical significance between the AI of these 2 groups and that of the normal breast epithelium (0.3%).
  • There was no statistical significance between the AI of these 2 groups and that of the normal breast epithelium (0.3%).
  • [MeSH-major] Apocrine Glands / pathology. Breast / pathology. Breast Neoplasms / pathology. Fibrocystic Breast Disease / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Division. Epithelium / metabolism. Epithelium / pathology. Female. Humans. In Situ Nick-End Labeling. Ki-67 Antigen / metabolism. Metaplasia. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / metabolism. Telomerase / metabolism. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20123450.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BAK1 protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-X Protein; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


5. Ashbeck EL, Rosenberg RD, Stauber PM, Key CR: Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev; 2007 Mar;16(3):467-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast biopsy diagnosis and subsequent risk of breast cancer.
  • BACKGROUND: We examine benign breast biopsy diagnoses as reported by community pathologists in New Mexico and investigate associations with future breast cancer development.
  • METHODS: Using data collected between 1992 and 2000 by the New Mexico Mammography Project and cancer data through 2003 from the New Mexico Tumor Registry, we calculated breast cancer rates following 14,602 benign breast biopsies for women ages 30 to 89 years.
  • For comparison, we also calculated the breast cancer rate following 215,283 normal screening mammograms.
  • RESULTS: We identified 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies and 4,402 breast cancer diagnoses among 215,283 women with mammograms assigned a "negative" or "benign finding" assessment.
  • Among low-risk histologic diagnoses, the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia.
  • Fibroadenoma, inflammation, and cysts did not exhibit an association with breast cancer development.
  • Women with low-risk diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, 1.68-2.60), whereas women with low-risk histologic diagnoses and dense breasts had a HR of 3.36 (95% CI, 2.83-3.99).
  • CONCLUSIONS: The observed breast cancer occurrence contributes to evidence of increased risk following benign biopsy.
  • The risk associated with histologic diagnoses in absence of atypia was twice the risk experienced by women with normal mammogram evaluations and may be modified by breast density.
  • [MeSH-major] Breast Diseases / pathology. Breast Neoplasms / pathology. Risk

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337650.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U01 CA69976
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


6. Strissel PL, Ellmann S, Loprich E, Thiel F, Fasching PA, Stiegler E, Hartmann A, Beckmann MW, Strick R: Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen. Int J Cancer; 2008 Dec 15;123(12):2871-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tamoxifen is an important selective estrogen receptor (ER) modulator for treatment of steroid hormone positive breast cancer.
  • We hypothesized that, (1) dysregulation of gene expression and protein phosphorylation of the insulin-like growth factor (IGF) and steroid hormone receptor-signaling occur early in benign endometrial tissues and (2) signaling differences would be detected between patients with or without tamoxifen treatment.
  • Seventy-eight tissues, including 2 benign cohorts from patients treated with (n = 24) or without tamoxifen (n = 28) (hyperproliferative endometrium, hyperplasia, polyps), EnCa (n = 12) with endometrium controls (n = 14) were analyzed for expression of 15 genes from the IGF and steroid hormone receptor-signaling, including the target genes Syncytin-1, PAX2 and c-myc.
  • Compared to controls similar significant deregulation of IGF and steroid hormone receptor-signaling, Syncytin-1 and PAX2 occurred in both benign cohorts, irrelevant of tamoxifen treatment.
  • Comparing both benign cohorts with and without tamoxifen significant expression differences were noted.
  • Increased total protein and phosphorylation of pERalpha-Ser118, pPTEN-Thr380, pAKT-Thr308, pAKT-Ser473, pmTOR-Ser2448 and Syncytin-1 were noted in early benign tissue stages associating with tamoxifen, especially polyps.
  • This study supports that dysregulated IGF and steroid hormone receptor signaling is prominent in endometrial benign stages and these alterations could represent clinical indicators for the risk of EnCa and also help in development of new therapies.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Biomarkers, Tumor / metabolism. Carcinoma / etiology. Endometrial Neoplasms / etiology. Estrogen Receptor Modulators / adverse effects. Insulin-Like Growth Factor I / metabolism. Tamoxifen / adverse effects

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18814240.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Estrogen Receptor Modulators; 0 / Gonadal Steroid Hormones; 094ZI81Y45 / Tamoxifen; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


7. Kamath A, Helie M, Bifulco CB, Li WW, Concato J, Jain D: Lack of immunohistochemical detection of VEGF in prostate carcinoma. Appl Immunohistochem Mol Morphol; 2009 May;17(3):227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Vascular endothelial growth factor (VEGF) has been implicated in tumor angiogenesis and is a potential therapeutic target in prostatic adenocarcinoma (PrCa).
  • Immunohistochemical (IHC) analysis has been used to demonstrate VEGF expression in PrCa, and in various other tumors including breast carcinoma, renal cell carcinoma, hepatocellular carcinoma, and gliomas.
  • Prior studies have reported markedly varied VEGF expression in benign prostatic hyperplasia (0% to 100%) and PrCa (40% to 100%).
  • RESULTS: Using different antibodies, positive staining of varying intensity was seen in benign glands, malignant glands, endothelial cells, and fibromuscular stroma.
  • CONCLUSIONS: Our results show that when nonspecific staining is blocked, no staining is found for VEGF within the prostate, in either benign or malignant glands.
  • Our study may help to explain variable results reported in previous studies, and suggests caution in interpreting VEGF expression in studies of PrCa and benign glands.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098681.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


8. Abdallah A, Saklaoui O, Stückle C, Sommerer F, Hatzmann W, Audretsch W, Wesemann A, Zink M, Skoljarev L, Papadopoulos S: [Case reports of operative management of very large, benign phylloid tumors--is a safety margin necessary?]. Gynakol Geburtshilfliche Rundsch; 2009;49(4):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case reports of operative management of very large, benign phylloid tumors--is a safety margin necessary?].
  • The phylloid tumor (PT, formerly called cystosarcoma phylloides) is a rare neoplasia of the female breast.
  • Usually the PT is treated with breast-conserving surgery.
  • In spite of progress in early diagnosis, PTs recur frequently--independently of tumor's degree of malignancy.
  • Especially in cases of malignant PT, complete resection with tumor-free margins is seen as the only predictive marker for tumor recurrence or metastases.
  • Benign PT is also often resected with wide tumor-free margins.
  • Because of the tumor's occasionally enormous dimensions, this therapy concept makes breast-conserving surgery almost impossible.
  • A simple enucleation of benign PT is an option to facilitate the preservation of breast tissue and a cosmetically satisfactory breast reconstruction.
  • In the case of particularly large benign PT, enucleation even without wide margins prevents tumor recurrence.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Subcutaneous / methods. Phyllodes Tumor / surgery
  • [MeSH-minor] Adult. Biopsy, Needle. Breast / pathology. Esthetics. Female. Follow-Up Studies. Humans. Mammaplasty / methods. Mammography. Middle Aged. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530948.001).
  • [ISSN] 1423-0011
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • Our objectives were to assess the relative level of CD133 expressing cells in primary human endometrial tumors, confirm their tumorigenic potential, and determine whether CD133 expression was epigenetically modified.
  • METHODS: We assessed CD133 expression in primary human endometrial tumors by flow cytometry and analyzed the relative tumorigenicity of CD133+ and CD133- cells in an in vivo NOD/SCID mouse model.
  • We further examined CD133 promoter methylation and expression in normal endometrium and malignant tumors.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-major] Antigens, CD / genetics. Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Epigenomics. Glycoproteins / genetics. Neoplastic Stem Cells / pathology. Peptides / genetics
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


10. Ziółkowska E, Pietrusińska E, Łozyńska-Podhrebelna D: [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue]. Pol Merkur Lekarski; 2008 Dec;25(150):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue].
  • Degradation of the extracellular matrix metalloproteinases, which are activated mainly by the plasmin (the key enzyme of the fibrinolysis system), is the basis of the invasion of breast cancer cells.
  • Shifting the balance between factors stimulating and inhibiting angiogenesis within the tumour microenvironment it influences negatively the progression of breast cancer.
  • The aim of the study was to estimate the concentration of t-PA levels in breast cancer tissue extracts in comparison with normal breast tissues as well as to analyze the t-PA level changes in relation to "classical" prognostic factors.
  • MATERIAL AND METHODS: A total number of 30 breast cancer patients aged from 39-79 (mean 58) years entered the study.
  • Additionally, in ten patients aged from 29-44 (mean 33) years the level of the t-PA in benign breast tissue lesions was determined.
  • Macroscopically normal tissues, which were located 2 cm from the tumor, served as a controls group.
  • RESULTS: The study showed no statistically significant difference between the levels of the t-PA in tumors and in normal tissues.
  • In terms of prognostic factors t-PA level was significantly higher in cancer tissues obtained from patients with no lymph node metastases as well as in tumors containing progesterone receptors.
  • The PgR levels were significantly higher in benign breast lesions in comparison with both, normal tissues and tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Tissue Plasminogen Activator / analysis
  • [MeSH-minor] Adult. Aged. Breast / chemistry. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen. Receptors, Progesterone. Reference Values. Tissue Extracts / chemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205379.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tissue Extracts; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


11. García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M: Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci; 2006 Oct;97(10):1044-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of tumor necrosis factor-alpha and its receptors in human benign breast lesions and tumors (in situ and infiltrative).
  • The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-alpha and its receptors in breast samples (benign diseases, in situ carcinomas and infiltrating carcinomas), and to compare these results with those obtained previously for interleukin-6, p53 and p21 using the same samples in order to elucidate the effects of these cytokines on the proliferation-apoptosis equilibrium.
  • The percentage of samples positive for TNF-alpha and TNFRII was higher in in situ carcinoma than in benign breast diseases, and TNFRII was even higher in infiltrating tumors.
  • In the positive samples, immunostaining for TNF-alpha was more intense in infiltrating tumors than in the other two patient groups, whereas immunostaining for both receptors was higher in in situ carcinoma than in benign breast diseases, and even higher in infiltrating tumors.
  • TNF-alpha might be an important factor in breast cancer promotion as its proliferation and survival effects seems to be enhanced through the increased expression of TNFRII.
  • Also, the pro-apoptotic pathway of TNFRI could be inhibited by p21 (which appeared increased in breast cancer), altering TNFRI effects in promoting the expression of several factors, such interleukin-6, which contribute to tumor promotion.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Receptors, Tumor Necrosis Factor, Type I / analysis. Receptors, Tumor Necrosis Factor, Type II / analysis. Tumor Necrosis Factor-alpha / analysis
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Humans. Immunohistochemistry. Interleukin-6 / analysis. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984377.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


12. Yu SE, Park SH, Jang YK: Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer. Mol Cells; 2010 Feb 28;29(2):217-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of TNFSF7 (CD70) by DNA methylation during progression to breast cancer.
  • To escape the immune system, tumor cells may remove surface molecules such as the major histocompatibility complex (MHC) and co-stimulatory molecules, which are essential for recognition by lymphocytes.
  • Down-regulation of the co-stimulatory molecules CD70 (TNFSF7) and CD80 may contribute to tumor cell survival; however, the mechanism of down-regulation of the TNFSF7 gene during tumorigenesis is poorly understood.
  • Here we present evidence indicating that TNFSF7 gene expression is epigenetically down-regulated via DNA hypermethylation within its promoter region during progression in breast cancer cells in the isogenic MCF10 model.
  • Bisulfite sequencing revealed that the CpG pairs at the proximal region of the TNFSF7 promoter are heavily methylated during progression of breast cancer cells but that methylation of the more distal sequences was not changed considerably.
  • Thus, this epigenetic silencing of the TNFSF7 gene via hypermethylation of its proximal region may allow the benign and invasive MCF10 variants to escape immune surveillance.
  • [MeSH-major] Antigens, CD70 / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA Methylation / genetics. Disease Progression. Gene Silencing
  • [MeSH-minor] Azacitidine / pharmacology. Base Sequence. Cell Line, Tumor. CpG Islands / genetics. Down-Regulation / drug effects. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Molecular Sequence Data. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20119871.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD70; 0 / CD70 protein, human; 0 / RNA, Messenger; M801H13NRU / Azacitidine
  •  go-up   go-down


13. Giorgi Rossi P, Federici A, Farchi S, Chini F, Barca A, Guasticchi G, Borgia P: The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy. J Med Screen; 2006;13(3):123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of screening programmes on the treatment of benign breast neoplasms: observations from current practice in Italy.
  • In this study, we compare the incidences of treatments for benign and malignant neoplasms in the two groups.
  • We linked all incident cases of surgery for benign and malignant breast neoplasms, from the Hospital Information System (1999-2003) to the Mammographic Screening Information System (1999-2001).
  • We calculated incidence, adjusted for age and standardized breast cancer mortality ratio in each area of residence, for benign and malignant neoplasms surgery in non-yet-contacted and contacted woman.
  • RESULTS: The target population in Lazio is 681,000; 116,000 women were contacted during the study period and 3252 malignant and 1566 benign neoplasms were surgically treated.
  • Annual incidence was, respectively, 2.0/1000 and 1.1/1000 for malignant and benign neoplasms in women not contacted, and, respectively, 2.9/1000 and 1.1/1000 in the contacted population.
  • About one-half of the surgeries for benign neoplasms in compliant women were treated against the recommendation of the screening programme.
  • CONCLUSIONS: The implementation of the screening programme did not increase the incidence of treatment for benign neoplasms, and detected 50% more malignant neoplasms.
  • [MeSH-major] Breast Neoplasms / epidemiology. Mammography. Mass Screening. Patient Compliance / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007652.001).
  • [ISSN] 0969-1413
  • [Journal-full-title] Journal of medical screening
  • [ISO-abbreviation] J Med Screen
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


14. Li JS, Sun GW, Wei XY, Tang WH: Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol; 2007 Oct 21;13(39):5261-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry was performed to localize and quantify the expression of periostin in benign gastric diseases and gastric cancer, and immunostaining results were correlated with gastric cancer pathological stages.
  • Immunohistochemical staining revealed that periostin was overexpressed in primary gastric cancer, as well as in metastatic lymph nodes, but only faint staining was found in benign gastric ulcers.
  • By quantitative analysis of the immunostaining results, periostin expression was increased 2.5-4-fold in gastric cancer, compared to that in benign gastric disease, and there was a trend toward increasing periostin expression with tumor stage.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876898.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC4171309
  •  go-up   go-down


15. Paradol PO, Toussoun G, Delbaere M, Delaporte T, Delay E: [Extra-abdominal desmoid tumor in a scar of donor-site of a latissimus dorsi flap: case report]. Ann Chir Plast Esthet; 2008 Feb;53(1):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extra-abdominal desmoid tumor in a scar of donor-site of a latissimus dorsi flap: case report].
  • [Transliterated title] Tumeur desmoïde extra-abdominale survenue sur cicatrice de prélèvement de lambeau de grand dorsal: à propos d'un cas.
  • We will discuss one case of desmoid tumor arising from a latissimus dorsi flap donor-site scar.
  • The subject was a 45 years old woman who had a breast reconstruction following mastectomy.
  • A dorsal tumefaction, with a benign aspect, was observed during the follow-up period.
  • The biopsy showed an extra-abdominal desmoid tumor.
  • [MeSH-major] Cicatrix / complications. Fibromatosis, Aggressive / etiology. Mammaplasty / adverse effects. Skin Neoplasms / etiology. Surgical Flaps / adverse effects


16. Wu J, Brinker DA, Haas M, Montgomery EA, Argani P: Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol; 2005 Jan;13(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
  • Alveolar soft part sarcoma (ASPS) is a rare neoplasm that most commonly presents in the lower extremities.
  • To our knowledge, only 1 case of ASPS arising within the breast has previously been reported.
  • The patient was a 44-year-old woman who presented with a breast mass.
  • The cells labeled strongly for the histiocytic marker CD68, suggesting a benign macrophage-rich lesion.
  • The diagnosis of ASPS was confirmed by electron microscopy, which revealed characteristic membrane-bound rhomboidal crystals, as well as by nuclear labeling for TFE3 protein by immunohistochemistry.
  • [MeSH-major] Breast Neoplasms / pathology. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Sarcoma / secondary. Soft Tissue Neoplasms / pathology. Transcription Factors. Xanthomatosis / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Antimetabolites, Antineoplastic / therapeutic use. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Biomarkers, Tumor / analysis. Cytoplasmic Vesicles / ultrastructure. Female. Humans. Microscopy, Electron, Transmission. Treatment Outcome

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735860.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA88843
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antimetabolites, Antineoplastic; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / DNA-Binding Proteins; 0 / TFE3 protein, human; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Brown B, Ram A, Clayton P, Humphrey G: Conservative management of bilateral Sertoli cell tumors of the testicle in association with the Carney complex: a case report. J Pediatr Surg; 2007 Sep;42(9):E13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management of bilateral Sertoli cell tumors of the testicle in association with the Carney complex: a case report.
  • Large cell calcifying Sertoli cell tumor of the testicle is a rare, hormonally active sex cord-stromal tumor seen in patients with Carney complex.
  • When such tumors occur bilaterally, treatment options for preserving fertility and addressing the secondary effects of excess hormone production must be considered.
  • The availability of specific antiestrogen drugs means that bilateral orchiectomy for this benign tumor may no longer be warranted.
  • Approximately two thirds of teenaged boys will develop some degree of breast enlargement that spontaneously regresses as testosterone levels rise (Ill Med J 1938;73:113).
  • In all cases, a thorough history and physical examination are required to exclude nonphysiologic causes such as drugs, pulmonary disease, chronic liver disease, exogenous estrogens, and estrogen-producing tumors (Seashore J.
  • Disorders of the breast.
  • We report on a child who presented with a 2-year history of gynecomastia with associated bilateral testicular swellings and discuss a novel treatment strategy for managing bilateral testicular tumors in the context of the Carney complex.
  • [MeSH-major] Multiple Endocrine Neoplasia / diagnosis. Sertoli Cell Tumor / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Carney Complex.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848226.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, Gao Y, Pan QJ: Analysis of the cellular centrosome in fine-needle aspirations of the breast. Breast Cancer Res; 2007;9(4):R48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the cellular centrosome in fine-needle aspirations of the breast.
  • BACKGROUND: The purpose of the present investigation is to determine whether centrosome amplifications are present in breast tumor cells, whether there are differences of centrosome amplification between benign breast lesions and breast carcinomas, and whether centrosomal analysis can be of value in the diagnosis and prognosis of breast carcinoma.
  • METHODS: Using immunofluorescence analysis with an antibody against gamma-tubulin, we analyzed centrosome abnormalities in fine-needle aspirations of 100 breast lesions (25 cases with benign lesions and 75 cases with carcinomas).
  • RESULTS: We found that centrosome amplifications, including numerical centrosome amplification and structural centrosome amplification, were present in most breast tumors.
  • Cells with numerical centrosome amplification were found in 23 of 25 benign lesions, and in all 75 cases of breast carcinomas.
  • Cells with structural centrosome amplification were found in three of 25 benign lesions, and in 69 of 75 breast carcinomas.
  • The breast carcinomas showed a mean percentage of cells with numerical centrosome amplification of 4.86% and a mean percentage of cells with structural centrosome amplification of 3.98%.
  • These percentages were significantly higher than those in benign lesions, with a numerical centrosome amplification of 2.77% and a structural centrosome amplification of 0.10%.
  • Furthermore, the mean percentage of cells with structural centrosome amplification was significantly associated with HER2/neu overexpression (P < 0.05) and with negative estrogen receptor status (P < 0.05), and had a borderline association with negative progesterone receptor status (P = 0.056) in breast carcinomas.
  • CONCLUSION: Structural centrosome amplification may bear a close relationship with breast carcinoma and may be a potential biomarker for diagnosis and prognosis of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Centrosome / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / pathology. DNA, Neoplasm / genetics. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Invasiveness. Prognosis. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2212-9 [11280789.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):137-41 [10425053.001]
  • [Cites] Cytopathology. 2001 Dec;12(6):390-8 [11843941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] Eur Urol. 2003 May;43(5):505-15 [12705995.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):346-52 [14506732.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):904-9 [14871819.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):746-51 [15499629.001]
  • [Cites] Science. 2005 Jan 7;307(5706):127-9 [15637283.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):389-95 [15558069.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] J Cell Biol. 1982 Sep;94(3):549-56 [7130271.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] J Cell Biol. 1998 Aug 10;142(3):775-86 [9700165.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):104-6 [9771694.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):963-70 [10353727.001]
  • [Cites] Lab Invest. 2001 Jul;81(7):945-52 [11454983.001]
  • (PMID = 17662154.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2206724
  •  go-up   go-down


19. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J, Pavelic K: Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol; 2005 Aug;79(1):42-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
  • The aims of this study were to assess the expression of protein products of c-myc, erbB-2, p53 and nm23-H1 gene in benign and malignant breast lesions, to estimate their possible coexpression and to correlate the results of immunohistochemical analysis with various clinicopathologic parameters.
  • Expression of c-myc protein was high in both malignant and benign lesions (95% and 100%).
  • These proteins were present in benign lesions as well: 7.8% of benign lesions were positive for erbB-2 protein and 19.6% for p53 protein.
  • The expression of nm23-H1 protein was similar in benign and malignant lesions: 47% and 54%.
  • We also found a negative correlation between the size of breast carcinomas and the expression of nm23-H1, a higher proportion of nm23-H1-positive carcinomas in the group of erbB-2-negative, p53-negative carcinomas and a higher proportion of nm23-H1-positive carcinomas in the group of malignant lesions with negative axillary lymph nodes.
  • Our results support the hypothesis that in women with breast cancer the expression of nm23-H1 gene may contribute to more favorable phenotype.
  • We also showed that some changes found in malignant breast tumors such as the presence of mutated p53 protein and the expression of erbB-2 protein may be found in benign lesions as well.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Nucleoside-Diphosphate Kinase / biosynthesis. Proto-Oncogene Proteins c-myc / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Breast Diseases / metabolism. Breast Diseases / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Mutation. NM23 Nucleoside Diphosphate Kinases. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005711.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


20. Schally AV: [The discovery of hypothalamic hormones and the development of antitumor analogs]. Ann Urol (Paris); 2005 Oct;39 Suppl 3:S46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La découverte des hormones hypothalamiques et le développement des analogues antitumoraux.
  • Although after the discovery of GnRH, research was initially directed towards the treatment of infertility, the development during the last twenty-five years of synthetic GnRH analogs has led to major advances in the diagnosis and treatment of endocrine disorders and cancer.
  • This has been used for the treatment of precocious puberty, in vitro fertilization protocols and management of various hormone-dependent cancers such as prostate and breast cancer, a field where these indications are being continually extended.
  • Their development is more recent, and they have begun to find a role in prostatic diseases, cancer and benign prostatic hypertrophy.
  • The management strategy of prostate, breast and ovarian cancers may therefore be considerably modified.
  • Likewise, this concept of targeted chemotherapy using analogs acting as cytotoxic agent carriers up to the tumor site is the aim of research to evaluate somatostatin and bombesin.
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / physiopathology. Female. Humans. Hypothalamus / physiology. Male. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / physiopathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302710.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 8
  •  go-up   go-down


21. Soares Leite D, Lima de Lima PD, Ferreira Leal M, Suchi Chen E, Casartelli C, de Arruda Cardoso Smith M, Rodríguez Burbano R: Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation. Clin Exp Med; 2006 Dec;6(4):166-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of chromosome 21 aneuploidies in breast fibroadenomas by fluorescence in situ hybridisation.
  • Fibroadenoma (FA) is a benign breast tumour that occurs in about 25% of women.
  • Cytogenetic studies suggest that numerical chromosomal aberrations may contribute to tumorigenesis, but chromosomal instability is still poorly characterised in breast cancer.
  • The aim of this study was to investigate numerical alterations of chromosome 21 in 15 breast FAs.
  • Classical cytogenetics analysis showed that all cells were diploidies with modal number varying between 43 and 47 chromosomes, and clonal chromosome alterations in 46.7% of tumours.
  • The study of benign proliferations and comparison with chromosome alterations in their malignant counterparts should result in an understanding of the genes acting in cell proliferation alone and those that cause these cells to both undergo malignant transformation and become invasive.
  • [MeSH-major] Aneuploidy. Breast Neoplasms / genetics. Chromosomes, Human, Pair 21 / genetics. Fibroadenoma / genetics. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191108.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


22. Hsiao YH, Huang YL, Kuo SJ, Liang WM, Chen ST, Chen DR: Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging. Eur J Radiol; 2009 Jul;71(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging.
  • PURPOSE: The authors assessed the characteristics of benign and malignant solid breast tumors in harmonic three-dimensional (3D) power Doppler imaging and proposed decision models to classify benign and malignant breast tumors.
  • MATERIALS AND METHODS: A total of 86 malignant and 97 benign harmonic 3D power Doppler US images were analyzed.
  • Histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), were calculated for the intra-tumor and for shells with an outside thickness of 3mm surrounding the breast tumors.
  • RESULTS: The results revealed that the choice of decision model comprised the parameters of patient age, intra-tumor VI, and tumor volume to classify benign and malignant breast tumors.
  • The parameter intra-tumor VI was the choice for all of the histogram indices in differentiating between malignant and benign lesions.
  • CONCLUSION: The decision model, which was composed of patient age, tumor volume and intra-tumor VI, and a cut-off value for intra-tumor VI at the upper end of patient age and tumor volume, was recommended in clinical application.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Imaging, Three-Dimensional / methods. Ultrasonography, Doppler / methods. Ultrasonography, Mammary / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479868.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


23. Lee JH, Kim SH, Lee ES, Kim YS: CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep; 2009 Nov;22(5):1149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of CD24 expression by immunohistochemistry was 68% in all the carcinomas of the breast, female genital tract, gastrointestinal tract, biliary tract and pancreas, urinary system, prostate and skin.
  • Overall, CD24 was more frequently overexpressed in their carcinomas than their benign lesions (OR=4.21; 95% CI, 1.826-9.731; P=0.001) and was significantly associated with lymph node metastasis (OR=2.41; CI, 1.013-5.720; P=0.047), advanced clinical stages (OR=1.59; 95% CI, 1.244-2.032; P<0.001) and shortened overall survival (HR=2.13; 95% CI, 1.656-2.730; P<0.001).
  • CD24 expression was highly associated with lymph node metastases in breast cancer (OR=3.55; 95% CI, 1.664-7.554; P=0.001), advanced clinical stages (OR=2.22; 95% CI, 1.442-3.418; P<0.001) and lymphovascular invasions (OR=2.78; 95% CI, 1.522-5.068; P=0.001) in urothelial carcinomas and with higher grades in endometrial adenocarcinomas (OR=3.88; 95% CI, 1.548-9.715; P=0.004).
  • CD24 was more frequently and strongly expressed in breast (OR=35.80; 95% CI, 8.907-143.921; P<0.001) and ovarian carcinomas (OR=35.92; CI, 7.156-180.311; P<0.001), than in their benign counterparts.
  • In particular, CD24 may promote cancer development and progression in the breast, ovary and urinary bladder.
  • [MeSH-major] Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Neoplasms / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787233.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Wilke LG, Brown JQ, Bydlon TM, Kennedy SA, Richards LM, Junker MK, Gallagher J, Barry WT, Geradts J, Ramanujam N: Rapid noninvasive optical imaging of tissue composition in breast tumor margins. Am J Surg; 2009 Oct;198(4):566-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid noninvasive optical imaging of tissue composition in breast tumor margins.
  • BACKGROUND: In women undergoing breast conserving surgery (BCS), up to 60% can require re-excision.
  • Our objective is to develop an optically based technology which can differentiate benign from malignant breast tissues intraoperatively through differences in tissue composition factors.
  • CONCLUSIONS: We present a novel optical spectral imaging device that provides a rapid, non-destructive assay of the tissue composition of breast tumor margins.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):846-8 [12088456.001]
  • [Cites] Curr Opin Biotechnol. 2009 Feb;20(1):119-31 [19268567.001]
  • [Cites] Am J Surg. 2002 Nov;184(5):383-93 [12433599.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):697-702 [12910512.001]
  • [Cites] CA Cancer J Clin. 1999 May-Jun;49(3):159-77 [10445015.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1058-64 [15522551.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jan;184(1):324-9 [15615996.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] J Am Coll Surg. 2005 Aug;201(2):194-8 [16038815.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1625-32 [16327435.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1062-71 [16512550.001]
  • [Cites] Appl Opt. 2006 Feb 10;45(5):1072-8 [16512551.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):509-12 [16978962.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):538-40 [16978970.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2953-60 [17674109.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3133-40 [17653798.001]
  • [Cites] J Am Coll Surg. 2008 Jan;206(1):76-82 [18155571.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1297-303 [18259820.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1271-2 [18320287.001]
  • [Cites] Cancer. 2008 May 1;112(9):1923-31 [18327818.001]
  • [Cites] J Biomed Opt. 2008 Mar-Apr;13(2):024012 [18465975.001]
  • [Cites] J Am Coll Surg. 2008 Jun;206(3):1116-21 [18501808.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2542-9 [18618180.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):556-8 [18809063.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2599-606 [18836763.001]
  • [Cites] Eur J Surg Oncol. 2009 Jan;35(1):32-7 [18539425.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jan;113(2):397-402 [18386174.001]
  • [Cites] J Biomed Opt. 2009 Jan-Feb;14(1):014024 [19256712.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1615-20 [19255332.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2919-26 [19293184.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1669-79 [19170229.001]
  • [Cites] Am J Surg. 2002 Aug;184(2):89-93 [12169349.001]
  • (PMID = 19800470.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024128; United States / NCRR NIH HHS / RR / UL1 RR024128-01; United States / NCRR NIH HHS / RR / 1UL1 RR024128-01
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS137679; NLM/ PMC2764289
  •  go-up   go-down


25. Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF: Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin (Barc); 2009 Oct 3;133(12):449-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
  • BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive tumor that can be difficult to diagnose, resulting in a delayed diagnosis in some cases.
  • Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in the diagnosis of MM.
  • PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had benign pleural effusion (8 infectious disease and 13 idiopathic effusion).
  • RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with benign effusion (P=0.02).
  • CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in the diagnosis of patients presenting with pleural effusion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Hematologic Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Biomarkers. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Male. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric


26. Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ: Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations. Am J Surg Pathol; 2009 Jan;33(1):111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the hereditary breast/ovary carcinoma genes BRCA1 or BRCA2 confer increased lifetime risk for ovarian, fallopian tube, and primary peritoneal carcinoma.
  • Transitional cell metaplasia is a benign epithelial alteration that is a common finding in the serosa of the tube but is underrecognized in the tubal fimbriae, where it may mimic tubal intraepithelial carcinoma.
  • Median tumor size was 2.7 mm (range: 1 to 11 mm).
  • No particular clinical variables (BRCA 1 vs. BRCA 2 mutation, parity, personal history of breast cancer, prior abdomino-pelvic surgery, or intraoperative findings) or benign pathologic alterations in the RRSO specimens were associated with the presence of transitional cell metaplasia of the fimbriae.
  • This study demonstrates that transitional cell metaplasia of the fimbriae is a common benign finding in RRSO specimens that should not be confused with the much less common finding of tubal intraepithelial carcinoma.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Fallopian Tubes / pathology. Genetic Predisposition to Disease
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Ovariectomy. Risk Factors. Tumor Suppressor Protein p53 / metabolism


27. Tao W, Kai F, Yue Hua L: Nipple adenoma in an adolescent. Pediatr Dermatol; 2010 Jul-Aug;27(4):399-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nipple adenoma is a rare tumor of the breast which usually appears in middle age women and rarely in adolescents.
  • Nipple adenoma is a benign neoplasia which should be recognized to avoid confusion with breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Nipples / pathology. Papilloma / pathology
  • [MeSH-minor] Adolescent. Carcinoembryonic Antigen / analysis. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653865.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


28. Michalopoulos NV, Zagouri F, Sergentanis TN, Pararas N, Koulocheri D, Nonni A, Filippakis GM, Chatzipantelis P, Bramis J, Zografos GC: Needle tract seeding after vacuum-assisted breast biopsy. Acta Radiol; 2008 Apr;49(3):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle tract seeding after vacuum-assisted breast biopsy.
  • PURPOSE: To assess cell seeding along the needle tract of vacuum-assisted breast biopsy (VABB).
  • In 2/31 (6.5%) cases (95% CI 0.8-21.4%), benign epithelial cell displacement was observed, and the duration of VABB was significantly longer in these two cases (52.5+/-3.5 min vs. 42.0+/-4.4 min for cases without benign cell displacement; P = 0.018, Mann-Whitney-Wilcoxon test for independent samples).
  • Benign cell displacement was associated with longer VABB duration.
  • The phenomenon of tumor cell dissemination along the needle tract is of questionable clinical significance when the treatment guidelines are followed.
  • [MeSH-major] Biopsy, Needle / adverse effects. Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Neoplasm Seeding

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365811.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


29. Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jiménez F, Massari N, Nuñez M, Cricco G, Martin G, Bergoc R, Rivera E: The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther; 2008 Jan;7(1):28-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment.
  • To better understand the importance of histamine in breast cancer development, the expression of histamine H3 (H3R) and H4 (H4R) receptors and their association with proliferating cell nuclear antigen (PCNA), histidine decarboxylase (HDC) and histamine content were explored in mammary biopsies.
  • Additionally, we investigated whether H3R and H4R were implicated in the biological responses triggered by histamine in MDA-MB-231 breast cancer cells.
  • The expression levels of H3R, H4R, PCNA, HDC and histamine content were determined by immunohistochemistry in 40 benign and malignant lesions.
  • Results indicate that H3R was detected in 67% (10/15) of benign lesions and in almost all carcinomas (24/25), being the level of its expression significantly higher in carcinomas (p = 0.0016).
  • The non-tumoral breast tissue surrounding carcinomas revealed a lower H3R expression compared to the tumor cells.
  • Only 13% (2/15) of the benign lesions expressed H4R compared to 44% (11/25) of the carcinomas.
  • Present findings demonstrate the presence of H3R and H4R in human mammary tissue and suggest that H3R may be involved in the regulation of breast cancer growth and progression representing a novel molecular target for new therapeutic approach.
  • [MeSH-major] Breast Neoplasms / etiology. Histamine / physiology. Receptors, G-Protein-Coupled / physiology. Receptors, Histamine / physiology. Receptors, Histamine H3 / physiology
  • [MeSH-minor] Adult. Aged. Breast / chemistry. Cell Movement / drug effects. Cell Proliferation / drug effects. Female. Histidine Decarboxylase / analysis. Humans. Imidazoles / pharmacology. Middle Aged. Proliferating Cell Nuclear Antigen / analysis. Thiourea / analogs & derivatives. Thiourea / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. THIOUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Jan;7(1):36-7 [18347416.001]
  • (PMID = 17932461.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HRH4 protein, human; 0 / Imidazoles; 0 / Proliferating Cell Nuclear Antigen; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Histamine; 0 / Receptors, Histamine H3; 145231-45-4 / clobenpropit; 820484N8I3 / Histamine; EC 4.1.1.22 / Histidine Decarboxylase; GYV9AM2QAG / Thiourea
  •  go-up   go-down


30. Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer; 2009 Nov 1;115(21):5038-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
  • BACKGROUND: : To prospectively assess fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) staging and prognosis value in patients with suspected inflammatory breast cancer (IBC).
  • METHODS: : Sixty-two women (mean age 50.7 +/- 11.4 years) presenting with unilateral inflammatory breast tumors (59 invasive carcinomas; 3 mastitis) underwent a PET/CT scan before biopsy.
  • RESULTS: : PET/CT scan was positive for the primary malignant tumor in 100% and false positive in 2 of 3 benign mastitis.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Inflammation / complications. Neoplasm Staging / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphatic Metastasis / radionuclide imaging. Middle Aged. Neoplasm Metastasis. Prognosis. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645022.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


31. de León DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, Cetina L, Coronel A, Hes O: Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer; 2009;9:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients.
  • BACKGROUND: Breast cancer is one of the main health problems in developed countries, occupying first place in mortality in women.
  • It is well-known that there are risk factors associated with breast cancer development.
  • Nonetheless, in 50-80% of cases known risk factors have not been identified, this has generated the attempt to identify new factors related with this neoplasia as viral infections.
  • The aim of this work is investigate the prevalence of HPV DNA in patients with breast lesions at the Instituto Nacional de Cancerologia de Mexico.
  • METHODS: Fifty-one cases of breast cancer were selected from the files of the institute and compared by age and tumor size with 43 cases of non malignant breast lesions (fibroadenoma, fibrocystic disease and phyllodes tumor).
  • RESULTS: All patients were mexican, mean age was 53.3, median age of menarche was 13 and median tumor size 9 cms.
  • In the group of benign conditions all were negative to HPV-DNA.
  • CONCLUSION: Presence of HPV in breast cancer in our group of cases is high in comparison to other authors; larger numbers of cases need to be analyzed in order to establish the exact role of this virus in the pathogenesis of breast cancer.
  • [MeSH-major] Breast Neoplasms / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):172-7 [17088061.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Sep;18(3):369-77 [10606184.001]
  • [Cites] Acta Oncol. 1999;38(7):931-8 [10606422.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):5057-61 [10697510.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):33-6 [11029768.001]
  • [Cites] J Hum Virol. 2001 Nov-Dec;4(6):329-34 [12082399.001]
  • [Cites] J Natl Cancer Inst. 2002 Dec 18;94(24):1832-6 [12488476.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):131-7 [14999143.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):384-6 [1320761.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(2):95-100 [1320958.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):121-35 [10326789.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):946-8 [16222323.001]
  • [Cites] Clin Breast Cancer. 2005 Dec;6(5):391-401 [16381622.001]
  • [Cites] J Pathol. 2006 Aug;209(4):436-44 [16710841.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(1):55-8 [17624590.001]
  • (PMID = 19161629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2636825
  •  go-up   go-down


32. Li YJ, Yang L, Xia Q, Wen G: [Hemodynamic changes in benign and malignant breast tumors and the mechanism]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug;29(8):1557-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemodynamic changes in benign and malignant breast tumors and the mechanism].
  • OBJECTIVE: To compare the histological morphology, hemodynamics and angiogenesis-related molecules between benign and malignant breast tumor and investigate their variation in different perfusion regions in the same type of tumors.
  • METHODS: Thirty patients with malignant breast carcinoma and 30 with breast fibroadenoma underwent contrast-enhanced ultrasound examination with time-intensity quantitative analysis.
  • RESULTS: The time-intensity curve (TIC) of malignant tumor group was characterized by rapid ascent and slow descent, while that of the benign group presented with slow ascent and rapid descent.
  • The AUC and WOT of the malignant tumor group were significantly higher than those of the benign group, while the PI and TTP showed no significant difference.
  • In malignant tumor group, PI, AUC and WOT on the margin of the foci were significantly higher those of the inside region, while TTP showed a reverse pattern.
  • No significant differences were found in the perfusion parameters between the inside and outside of the foci in the benign group.
  • The distribution of CD34 was heterogeneous in breast carcinoma, and the micro-vessels were densely distributed especially on the margin of the cancer nest.
  • The microvessel density of the malignant group (34.48-/+8.34) was significantly higher than that of the benign group (18.65-/+4.69).
  • Diffuse or focal high VEGF expression was found on the margin of the cancer nest and necrotic tissue, but hardly detected in the benign group.
  • Flk-1/KDR expressed diffusely or focally in breast carcinoma with especial high expression on the margin of the cancer nest and necrotic tissue, but was virtually undetectable in the benign group.
  • CONCLUSION: The perfusion pattern, TIC, mean perfusion parameter and variation of the regional perfusion parameters provide valuable evidence for differential diagnoses between benign and malignant breast tumors.
  • Molecular imaging targeting VEGF and Flk-1/KD shed light on new approaches to early diagnosis of breast carcinoma.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / pathology. Hemodynamics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726291.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


33. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Alvarenga M, Vassallo J: p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):71-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast?
  • The immunohistochemical detection of myoepithelial cells in benign sclerosing lesions of the breast is useful in distinguishing them from tubular carcinoma.
  • The authors assessed the use of p63 and CD10 in the differential diagnosis between benign sclerosing lesions, such as sclerosing adenosis and radial scar, and tubular carcinoma, in comparison to the traditional myoepithelial markers 1A4 and calponin. p63, CD10, 1A4, and calponin were expressed in myoepithelial cells of all benign lesions and were consistently negative in all cases of tubular carcinoma.
  • In conclusion, p63 and CD10 may be used as a complement to 1A4 in distinguishing benign sclerosing lesions from tubular carcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540734.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


34. Port ER, Patil S, Stempel M, Morrow M, Cody HS 3rd: Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment? Cancer; 2010 Apr 15;116(8):1987-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
  • BACKGROUND: Sentinel lymph node (SLN) biopsy has been well-established for axillary lymph node staging for patients with breast cancer.
  • Among patients with negative SLNs, the authors observed variation by tumor size and patient age in the total number of lymph nodes removed (SLNs plus non-SLNs).
  • METHODS: Retrospective review of this institution's SLN database identified 4103 SLN biopsy procedures between 1997 and 2004 in which SLN biopsy was performed for prophylactic mastectomy, ductal carcinoma in situ, or T1 to T2 invasive cancers, and the SLNs were benign.
  • RESULTS: The mean number of SLNs, non-SLNs, and total lymph nodes for all tumor sizes was 2.8, 1.5, and 4.3, respectively, and increased with tumor size (more lymph nodes were removed for T2 than for T1 tumors: 6.3 vs 4.3; P < .0001).
  • CONCLUSIONS: The morbidity of SLN biopsy is less than that of ALND, but for pN0 patients, the total number of lymph nodes removed increased with tumor size and younger patient age.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Sentinel Lymph Node Biopsy / adverse effects
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Axilla / surgery. Bias (Epidemiology). Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20151427.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kono S, Kurosumi M, Simooka H, Kawanowa K, Takei H, Suemasu K: Nipple adenoma found in a mastectomy specimen: report of a case with special regard to the proliferation pattern. Breast Cancer; 2007;14(2):234-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of nipple adenoma incidentally found in a mastectomy specimen, and describe its unique histological appearance and the immunohistochemical distribution of Ki-67 positive tumor cells.
  • A 45-year-old woman with no symptoms or sign related to the nipple had a left mastectomy for invasive breast cancer.
  • A small nipple adenoma, 7 mm in size, was incidentally recognized in the nipple of the resected breast.
  • Histologically, the tumor in the nipple was composed of numerous proliferative ducts with a tubular and florid papillomatous appearance.
  • Many demarcations between squamous cells of the epidermis and tumor cells were recognized in the summit as well as the lateral wall of the nipple.
  • A high Ki-67 labeling index (20.3%) was recognized in the tumor cells in the superficial region, and a low labeling index (0.7%) was seen in the deeper region of the tumor.
  • Based on these proliferative patterns, the symptoms and clinical signs related to the nipple that are often found in patients with nipple adenoma are thought to be associated with the destruction of the epidermis of the nipple by the invasion of benign tumor cells with high proliferative activity.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Mastectomy. Nipples / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485911.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


36. Zeng Y, Yang WT, Zhang GH, Zhu XZ: [Study of HOXA5 gene expression in breast carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of HOXA5 gene expression in breast carcinoma].
  • OBJECTIVE: To study mRNA and protein expression of HOXA5 gene in breast carcinoma, to correlate the expression of HOXA5 gene with clinicopathologic parameters and to explore the possible role of HOXA5 gene in carcinogenesis, progression and metastasis of breast carcinoma.
  • METHODS: TaqMan real-time reverse transcriptase-polymerase chain reaction (RT-PCR) was applied on 60 cases of primary breast carcinoma and 24 cases of benign mammary lesions in order to detect mRNA expression of HOXA5 gene.
  • Statistical analysis was carried out to analyze the correlation between HOXA5 gene expression and various clinical parameters in these breast cancer patients. RESULTS:.
  • (1) The relative expression level of HOXA5 mRNA ranged from 0.73 to 193.07 (average = 20.85) in primary breast carcinoma, in contrast to 5.42 to 81.91 (average = 30.94) in benign mammary lesions.
  • Compared with benign mammary lesions, a significant reduction in expression of HOXA5 mRNA was noted in primary breast carcinoma (P < 0.01). (2) There was a decreased or completely diminished HOXA5 protein expression in breast carcinoma. (3) HOXA5 mRNA expression was significantly lower in lymph node-positive cases, when compared with that in lymph node-negative cases (P < 0.05).
  • On the other hand, moderately or strongly positive HOXA5 staining was noted in lymph node-negative cases. (4) Neither mRNA nor protein expression of HOXA5 gene correlated with clinicopathologic parameters such as age of patients, size of tumor, clinical stage, pathologic subtype or histologic grade (P > 0.05).
  • CONCLUSIONS: Disordered expression of HOXA5 gene may play a role in the carcinogenesis of breast cancer.
  • Reduced expression of HOXA5 gene may be related to the metastatic potential of breast carcinoma cells.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Homeodomain Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast / metabolism. Breast / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468307.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HOXA5 protein, human; 0 / Homeodomain Proteins; 0 / RNA, Messenger
  •  go-up   go-down


37. Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, Edmondson R, Darby S, Berchuck A, Laird PW, Pearce CL, Ramus SJ, Jacobs IJ, Gayther SA: Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia; 2010 Jul;12(7):579-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used a functional complementation approach to identify tumor-suppressor genes and putative therapeutic targets for ovarian cancer.
  • Using immunohistochemistry, 66% of 794 invasive ovarian tumors showed no EPB41L3 expression compared with only 24% of benign ovarian tumors and 0% of normal ovarian epithelial tissues.
  • EPB41L3 was extensively methylated in ovarian cancer cell lines and primary ovarian tumors compared with normal tissues (P = .00004), suggesting this may be the mechanism of gene inactivation in ovarian cancers.
  • [MeSH-major] Chromosomes, Human, Pair 18 / genetics. Gene Transfer Techniques. Membrane Proteins / physiology. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Apoptosis / genetics. Cell Culture Techniques. Cells, Cultured. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Genetic Association Studies. Humans. Hybrid Cells / metabolism. Hybrid Cells / pathology. Microarray Analysis. Microfilament Proteins. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechnol Bioeng. 2003 Jul 20;83(2):173-80 [12768623.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):417-23 [12543797.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8648-55 [14695176.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):40-5 [14702039.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3957-71 [15082789.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):190-203 [15138999.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):247-60 [15139003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1466-9 [274733.001]
  • [Cites] Somatic Cell Genet. 1981 Nov;7(6):699-712 [7323948.001]
  • [Cites] Mol Cell Biol. 1985 Jan;5(1):140-6 [3982414.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):68-76 [7606932.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1545-51 [10102624.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):869-79 [15580292.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):522-30 [15737618.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2954-61 [15837747.001]
  • [Cites] Int J Mol Med. 2005 Oct;16(4):771-4 [16142420.001]
  • [Cites] Genetics. 2005 Oct;171(2):783-90 [15956674.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10052-9 [16260618.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):545-51 [16125217.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):225-35 [16258702.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):916-23 [16152585.001]
  • [Cites] BMC Bioinformatics. 2006;7:264 [16716215.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9682-90 [17018626.001]
  • [Cites] Mol Ther. 2006 Dec;14(6):872-82 [16904943.001]
  • [Cites] Mol Cancer. 2007;6:14 [17280610.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):141-6 [17413980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12784-9 [17640904.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):780-94 [17877616.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):819-23 [17415786.001]
  • [Cites] Mol Cancer. 2006;5:4 [16420693.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2489-97 [18381458.001]
  • [Cites] N Engl J Med. 2008 Apr 3;358(14):1454-64 [18385497.001]
  • [Cites] Mol Cancer Res. 2008 Apr;6(4):592-603 [18403638.001]
  • [Cites] RNA. 2008 May;14(5):878-87 [18369183.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):401-8 [18449890.001]
  • [Cites] Pathology. 2008 Aug;40(5):487-92 [18604735.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4372-7 [18628450.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1529-38 [18528427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16719-24 [18940925.001]
  • [Cites] Biosci Rep. 2008 Dec;28(6):319-26 [18666890.001]
  • [Cites] Int J Cancer. 2009 Mar 1;124(5):1037-44 [19058220.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):234-9 [19136951.001]
  • [Cites] Cell Prolif. 2009 Apr;42(2):219-28 [19222485.001]
  • [Cites] Hum Mol Genet. 2009 May 15;18(10):1869-78 [19270026.001]
  • [Cites] Cell Prolif. 2009 Jun;42(3):385-93 [19397591.001]
  • [Cites] Genome Res. 2000 Dec;10(12):1878-89 [11116084.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6277-85 [11175342.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):314-9 [11313960.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):131-7 [11566343.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 15;130(2):118-26 [11675132.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):97-103 [11921287.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):145-55 [12086873.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):181-8 [12115567.001]
  • [Cites] Nature. 2003 Dec 4;426(6966):570-4 [14654843.001]
  • (PMID = 20651987.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801875; United States / NCI NIH HHS / CA / R01 CA096958
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2907584
  •  go-up   go-down


38. Gisterek I, Matkowski R, Lacko A, Sedlaczek P, Szewczyk K, Biecek P, Halon A, Staszek U, Szelachowska J, Pudelko M, Bebenek M, Harlozinska-Szmyrka A, Kornafel J: Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res; 2010 Sep;16(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factors a, C and d in human breast tumors.
  • Available evidence suggests that vascular endothelial growth factor (VEGF) a potent regulator of vasculogenesis and tumor angiogenesis may be a predictor of recurrence in breast cancer patients.
  • We sought to determine whether VEGF serum levels (VEGF-A, VEGF-C and VEGF-D) in 377 patients with malignant and benign breast tumors differ and whether there is association between vascular growth factors, clinicopathologic features and prognosis.
  • In Cox model values of angiogenic serum markers and recognized prognostic markers in breast cancer, VEGF-C turned out as independent prognostic factor.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor C / blood. Vascular Endothelial Growth Factor D / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / mortality. Neovascularization, Pathologic / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Jun 1;94(11):2855-61 [12115372.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4370-9 [15806151.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):512-7 [16750560.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1794-7; discussion 1797-8 [17465468.001]
  • [Cites] Indian J Med Res. 2007 Jun;125(6):747-51 [17704550.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4695-704 [16034044.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):467-83 [15982726.001]
  • [Cites] J Cell Mol Med. 2007 Jan-Feb;11(1):120-8 [17367506.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] Tumour Biol. 2006;27(6):302-8 [17028465.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):928-33 [15383417.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1217-22 [12973845.001]
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):978-85 [17912242.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):724-30 [15637689.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3121-8 [9738584.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):135-43 [15692755.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Sep;24(5):426-30 [10542924.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):159-64 [11437102.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 19821158.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


39. Penco S, Rizzo S, Bozzini AC, Latronico A, Menna S, Cassano E, Bellomi M: Stereotactic vacuum-assisted breast biopsy is not a therapeutic procedure even when all mammographically found calcifications are removed: analysis of 4,086 procedures. AJR Am J Roentgenol; 2010 Nov;195(5):1255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic vacuum-assisted breast biopsy is not a therapeutic procedure even when all mammographically found calcifications are removed: analysis of 4,086 procedures.
  • OBJECTIVE: The purpose of our study was to assess whether in case of total removal of microcalcifications there is still residual tumor on the surgical specimen and, secondarily, to assess whether complete rather than partial excision of the imaging target with microcalcifications may result in increased diagnostic accuracy.
  • MATERIALS AND METHODS: We retrospectively reviewed 4,086 stereotactic vacuum-assisted breast biopsy (VABB) procedures for microcalcifications and histologic findings to determine the frequency of malignancy, histologic underestimation, and complete removal of cancer.
  • RESULTS: No residual microcalcifications on postbiopsy mammograms were seen in 1,594 of 4,047 (39.4%) procedures successfully completed: 351 of 1,594 lesions were malignant, 1,109 benign and 134 atypical.
  • [MeSH-major] Biopsy / methods. Breast Diseases / pathology. Breast Diseases / surgery. Calcinosis / pathology. Calcinosis / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms / surgery. Chi-Square Distribution. Humans. Mammography. Middle Aged. Retrospective Studies. Vacuum

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966337.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Shimoyama T, Kimura B: [Peripheral intrapulmonary lipoma: report of a case]. Kyobu Geka; 2009 Dec;62(13):1186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 62-year-old woman who had undergone a left mastectomy for a breast cancer consulted us for an abnormal chest shadow.
  • The differential diagnosis included benign lung tumors, such as intrapulmonary lymph nodes, granuloma etc.
  • To make diagnosis, a wedge resection of the pulmonary nodule was performed.
  • The tumor was diagnosed as a lipoma.
  • Although peripheral intrapulmonary lipoma is very rare, it should be kept in mind in the differential diagnosis of an intrapulmonary nodule.
  • [MeSH-major] Lipoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999101.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


41. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer; 2010 Apr;68(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
  • In the case of malignancy the further challenge is to distinguish metastatic tumors from the primary malignant mesothelioma.
  • The first objective of this study was to adapt the commercial FISH-test, UroVysion originally designed for the cytological diagnosis of bladder cancer, to the analysis of cells in effusions.
  • The cytological diagnosis was malignant in 29 cases, inconclusive in 24 cases and benign in 15 cases.
  • The independently verified final diagnoses were mesothelioma in 21 cases, metastatic cancer in 29 and benign in 18 cases.
  • The algorithm for aneuploidy distinguished almost all tested malignant conditions from benign ones, also those with inconclusive cytology.
  • [MeSH-major] Breast Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Aneuploidy. Diagnosis, Differential. Female. Genes, p16. Humans. Pleural Effusion, Malignant / pathology. Reagent Kits, Diagnostic. Sequence Deletion / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19523712.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


42. Grubstein A, Yepes M, Kiszonas R: Magnetic resonance imaging of breast vascularity in medial versus lateral breast cancer. Eur J Radiol; 2010 Aug;75(2):e9-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of breast vascularity in medial versus lateral breast cancer.
  • OBJECTIVE: Breasts with malignant tumors can demonstrate a general increased vascularity compared to the contralateral breast and a prominent blood vessel adjacent to the tumor on magnetic resonance imaging (MRI).
  • The aim of the study was to further characterize these alterations in blood supply by location of the tumor within the breast using MRI.
  • MATERIALS AND METHODS: The study group included 105 patients who underwent breast MRI for suspicion of a malignancy over a 2-year period.
  • Fifty-one had pathologically verified malignant tumors (study group), 11 had pathologically verified benign lesions (control), and 43 had negative scans (control).
  • The malignant lesions were distinguished by location, medial or lateral, within the breast.
  • RESULTS: Of the 24 medial malignant tumors, 21 (87%) had a predominantly medial vascular supply and 3 (13%), a predominantly lateral supply; of the 23 lateral tumors, 11 (48%) had a predominantly medial vascular supply and 8 (35%), a predominantly lateral supply (p=0.03).
  • General increased vascularity was demonstrated in 91% of the medial tumor subgroup and 83% of the lateral tumor subgroup, as opposed to 36-37% in the control groups (p<0.0005).
  • Follow-up MRI, performed in 8 patients in the malignant-tumor group after treatment, revealed a considerable decrease in the prominent vessels, to a size close to that of the controls.
  • CONCLUSION: Breasts with malignant tumors are characterized by an altered general vascular supply, a prominent feeding vessel, and increased regional vascularity.
  • Both the presence and location of the tumor affect the vascular supply.
  • [MeSH-major] Breast / blood supply. Breast Neoplasms / blood supply. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19926240.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


43. Bratthauer GL, Strauss BL, Tavassoli FA: STAT 5a expression in various lesions of the breast. Virchows Arch; 2006 Feb;448(2):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] STAT 5a expression in various lesions of the breast.
  • Using a monoclonal antibody, we tested 100 formalin-fixed, paraffin-embedded breast tissues representing everything from simple hyperplasia to invasive carcinoma for the expression of STAT 5a in comparison to normal breast epithelial cells.
  • STAT 5a was found in endothelial cells, adipocytes, and leukocytes as well as in the cytoplasm and nucleus of normal epithelial cells, usual ductal hyperplasia, and benign lesions such as fibroadenoma.
  • A few examples of lobular intraepithelial neoplasia and invasive carcinoma demonstrated some reactivity, albeit comparatively reduced.
  • The absence of STAT 5a in the abnormal breast epithelial cells may indicate a defect contributory to the abnormal state.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. STAT5 Transcription Factor / biosynthesis
  • [MeSH-minor] Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Hyperplasia. Immunohistochemistry. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 1995 May;57(5):799-803 [7539031.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:759-66 [10642538.001]
  • [Cites] Stem Cells. 1999;17(3):138-46 [10342556.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):607-19 [15382041.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Mar;2(3):116-7 [16264885.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):1108-24 [11981045.001]
  • [Cites] Breast Cancer Res Treat. 2004 Dec;88(3):263-72 [15609129.001]
  • [Cites] Mol Cell Endocrinol. 1999 Dec 20;158(1-2):45-54 [10630404.001]
  • [Cites] Endocrinology. 2001 Nov;142(11):5015-26 [11606470.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] J Leukoc Biol. 2001 Sep;70(3):348-56 [11527983.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):720-5 [10699955.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):173-83 [11325527.001]
  • [Cites] Oncogene. 2003 Mar 20;22(11):1638-52 [12642867.001]
  • [Cites] Dev Biol. 2001 Jan 1;229(1):163-75 [11133161.001]
  • [Cites] Mol Biol Cell. 1999 Oct;10(10):3463-71 [10512880.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40026-31 [12874294.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):524-32 [12888825.001]
  • [Cites] Cell Mol Life Sci. 1999 Sep;55(12):1559-67 [10526573.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):460-5 [11331873.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):746-60 [15592524.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584.001]
  • [Cites] Mol Endocrinol. 1995 Nov;9(11):1598-609 [8584036.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2358-65 [11290598.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):894-900 [9647789.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1449-60 [15509516.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):531-42 [11706048.001]
  • [Cites] Biochim Biophys Acta. 1999 Nov 11;1452(2):188-96 [10559472.001]
  • (PMID = 16133357.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


44. Cheng Z, Xiuzhen D, Feng F, Zhenyu J, Canhua X: Breast cancer detection based on multi-frequency EIS measurement. Conf Proc IEEE Eng Med Biol Soc; 2007;2007:4158-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer detection based on multi-frequency EIS measurement.
  • As a convenient, un-injurious and low cost method for women breast tumor diagnosis, Electrical Impedance Scanning (EIS) is being paid increasing attention.
  • In theory the malignant tumor has higher electrical conductivity than normal tissue and benign tumor, so the cancer will be recognized in the EIS image as a bright spot.
  • In many cases it is difficult to judge whether a suspicious bright spot tells a malignant or benign tumor.
  • Because the malignant and the benign tumor have different curves in electrical conductivity-frequency diagram, we can analyze the data at every frequency and find out the attribute of the tumor.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Electric Impedance. Image Processing, Computer-Assisted

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18002918.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Abdel Salam I, Gaballa HE, Abdel Wahab N: Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol; 2009;26(2):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 30 patients with pathologically proven NSCLC were enrolled in this study in addition to ten normal controls subjects and ten cases with benign pulmonary diseases as broncheicatsis, chronic obstructive pulmonary disease.
  • The levels were significantly higher in those with stages III, IV compared with I, II, and in those with higher grades of the tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood. Receptor, ErbB-2 / blood


46. Udapudi DG, Vasudeva P, Srikantiah R, Virupakshappa E: Massive benign phyllodes tumor. Breast J; 2005 Nov-Dec;11(6):521
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive benign phyllodes tumor.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Phyllodes Tumor / pathology. Phyllodes Tumor / surgery

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297126.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Anderson NS, Turner L, Livingston S, Chen R, Nicosia SV, Kruk PA: Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation. J Ovarian Res; 2009;2:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation.
  • The ovarian tumor microenvironment is comprised of tumor cells, surrounding stroma, and circulating lymphocytes, an important component of the immune response, in tumors.
  • Previous reports have shown that the anti-apoptotic protein Bcl-2 is overexpressed in many solid neoplasms, including ovarian cancers, and contributes to neoplastic transformation and drug-resistant disease, resulting in poor clinical outcome.
  • Therefore, we sought to examine Bcl-2 expression in normal, benign, and cancerous ovarian tissues to determine the potential relationship between epithelial and stromal Bcl-2 expression in conjunction with the presence of lymphocytes for epithelial ovarian tumor progression.
  • METHODS: Ovarian tissue sections were classified as normal (n = 2), benign (n = 17) or cancerous (n = 28) and immunohistochemically stained for Bcl-2.
  • RESULTS: While Bcl-2 staining remained cytoplasmic, both percent and intensity of epithelial and stromal Bcl-2 staining decreased with tumor progression.
  • Further, the number of lymphocyte nests dramatically increased with tumor progression.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):29-39 [11325514.001]
  • [Cites] Int J Oncol. 2001 May;18(5):965-72 [11295042.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2061 [10561259.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):93-107 [10732792.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2891-902 [19472394.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):58-64 [19258943.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):393-402 [19060844.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):60-7 [19007973.001]
  • [Cites] Breast. 2008 Dec;17(6):604-10 [18656354.001]
  • [Cites] Adv Exp Med Biol. 2008;622:79-87 [18546620.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):316-24 [16505286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] J Surg Oncol. 2005 Dec 15;92(4):337-43 [16299808.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):797-812 [16127158.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] Breast Cancer Res. 2005;7(1):33-6 [15642180.001]
  • [Cites] Mol Biol Cell. 1999 Apr;10(4):1221-34 [10198068.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):517-24 [9516944.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2178-84 [8616869.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):261-5 [9365533.001]
  • [Cites] Br J Urol. 1997 Apr;79 Suppl 2:18-26 [9126066.001]
  • [Cites] Am J Clin Pathol. 1996 Mar;105(3):341-9 [8602616.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1324-9 [7577491.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):67-74 [7557618.001]
  • [Cites] Obstet Gynecol. 1993 Aug;82(2):181-6 [8336861.001]
  • [Cites] Int J Dev Biol. 1993 Mar;37(1):203-11 [8507562.001]
  • [Cites] Biol Reprod. 1991 Apr;44(4):717-24 [1710511.001]
  • [Cites] Int J Cell Cloning. 1991 Sep;9(5):438-50 [1955735.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):843-6 [2010226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 [2424019.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2750-4 [2713858.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4450-6 [15240536.001]
  • [Cites] Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76 [12060448.001]
  • (PMID = 19852858.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2774291
  •  go-up   go-down


48. Vasaturo F, Sallusti E, Gradilone A, Malacrino C, Nardo T, Avagnano G, Aglianò AM, Granato T, De Vincenzi B, Coppotelli G, Marzullo A, Soda G, Simonelli L, Modesti M, Scarpa S: Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast. Int J Oncol; 2005 Oct;27(4):1005-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
  • The expression of the extracellular matrix-related genes, such as fibronectin, laminin and tenascin C, and apoptosis-related genes, such as bax, bcl2 and survivin, was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry in normal breast tissue and benign and malignant breast tumors and then correlated to several clinical parameters: estrogen and progesterone receptors, Ki67, ErbB2, tumor size, lymph node status and grading.
  • Seventy-three breast tissue samples were examined.
  • In addition, we found a statistically significant increase in survivin transcription in malign tumors compared to fibroadenomas (P=0.024).
  • The negative correlation between laminin transcription and Ki67 could suggest that laminin impacts negatively on tumor proliferation, and the positive correlation between fibronectin and lymph node status may lead to consider fibronectin as predictive of long distance metastasis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor. Breast Diseases / metabolism. Breast Neoplasms / metabolism. Carcinoma / metabolism. Extracellular Matrix / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cytoplasm / metabolism. Female. Fibronectins / metabolism. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Ki-67 Antigen / biosynthesis. Laminin / metabolism. Lymphatic Metastasis. Microtubule-Associated Proteins / metabolism. Neoplasm Metastasis. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA / metabolism. Receptor, ErbB-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tenascin / metabolism. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142317.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Inhibitor of Apoptosis Proteins; 0 / Ki-67 Antigen; 0 / Laminin; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tenascin; 0 / bcl-2-Associated X Protein; 63231-63-0 / RNA; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


49. Perk J, Gil-Bazo I, Chin Y, de Candia P, Chen JJ, Zhao Y, Chao S, Cheong W, Ke Y, Al-Ahmadie H, Gerald WL, Brogi E, Benezra R: Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res; 2006 Nov 15;66(22):10870-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the importance of Id1 in tumor endothelial cells is well established, the expression and role of the Id1 protein in human cancer cells is controversial.
  • To explore this issue, we developed and characterized a highly specific rabbit monoclonal antibody against Id1 to assess its expression in human breast, prostate, and bladder malignancies.
  • Interestingly, we detected nuclear expression of the Id1 protein in the tumor cells in 10 of 45 cases of poorly differentiated and highly aggressive carcinoma with metaplastic morphology.
  • Similarly, only 1 of 30 prostate cancer samples showed Id1-positive tumor cells, whereas in almost all, endothelial cells showed high Id1 expression.
  • Intriguingly, whereas normal prostate glands do not show any Id1 protein expression, basal layer cells of benign prostate glands in proximity to tumors expressed high levels of the Id1 protein.
  • In contrast to the lack of Id1 expression in the usual types of mammary and prostate cancers, the majority of transitional cell bladder tumors showed Id1 protein expression in both tumor and endothelial cells.
  • These results suggest that further refinement of Id1 expression patterns in a variety of tumor types will be necessary to identify and study the functional roles played by Id1 in human neoplastic processes.
  • [MeSH-major] Inhibitor of Differentiation Protein 1 / biosynthesis. Neoplasms / metabolism
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Endothelial Cells / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Male. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Rabbits. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ID1 protein, human; 0 / Inhibitor of Differentiation Protein 1
  •  go-up   go-down


50. Corben AD, Lerwill MF: Use of Myoepithelial Cell Markers in the Differential Diagnosis of Benign, In situ, and Invasive Lesions of the Breast. Surg Pathol Clin; 2009 Jun;2(2):351-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Myoepithelial Cell Markers in the Differential Diagnosis of Benign, In situ, and Invasive Lesions of the Breast.
  • Immunohistochemical markers for myoepithelial cells are commonly used to distinguish invasive from noninvasive lesions in the breast.
  • The approach takes advantage of the fact that conventional invasive carcinomas lack surrounding myoepithelial cells, whereas nearly all benign lesions and in situ carcinomas retain their myoepithelial cell layer.
  • Although conceptually straightforward, the interpretation of myoepithelial cell markers can be complicated by misleading patterns of reactivity (such as stromal or tumor cell staining) or lack of reactivity (due to reduced numbers of myoepithelial cells or variable antigenicity).
  • Myoepithelial cell markers can be diagnostically useful in the distinction of many benign, in situ, and invasive lesions, but they must be interpreted in conjunction with careful morphologic analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009. Published by Elsevier Inc.
  • (PMID = 26838326.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Breast / Calponin / In situ carcinoma / Invasive carcinoma / Myoepithelial cell / Smooth muscle actin / Smooth muscle myosin heavy chain / p63
  •  go-up   go-down


51. Ichihara S, Ikeda T, Kimura K, Hanatate F, Yamada F, Hasegawa M, Moritani S, Yatabe Y: Coincidence of mammary and sentinel lymph node papilloma. Am J Surg Pathol; 2008 May;32(5):784-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old Japanese female underwent 5 needle manipulations and 2 surgical biopsies for recurring papillomas in the right breast over 5 years before having a simple mastectomy.
  • During the mastectomy, the ipsilateral sentinel node was found to be extensively occupied by completely benign papilloma that measured 6 mm in its greatest dimension.
  • The presence of myoepithelial layer in each papillary tumor was confirmed by immunostains with specific myoepithelial markers, p63 and CD10.
  • The excisional biopsy specimen exhibited displaced fragments of benign epithelial cells within granulation tissue at the needle manipulation site, indicating that iatrogenic epithelial cell displacement did occur in this case.
  • It remains undetermined whether the nodal papilloma was derived from the papilloma of the mastectomy or if it arose de novo from the breast tissue inclusion of the sentinel node.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes / pathology. Papilloma, Intraductal / secondary. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379415.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


52. Kosmas P, Laranjeira S, Dixon JH, Li X, Chen Y: Time reversal microwave breast imaging for contrast-enhanced tumor classification. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:708-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time reversal microwave breast imaging for contrast-enhanced tumor classification.
  • This paper studies the decomposition of the time reversal operator (DORT, by the French acronym) technique for microwave breast lesion classification.
  • We apply the finitedifference time-domain (FDTD) method to a realistic numerical breast phantom where lesion-like targets are artificially introduced, and obtain the multistatic data matrix (MDM) for a particular antenna array configuration.
  • Then, the singular value decomposition (SVD) of this matrix is derived for different targets, which represent malignant and benign lesions.
  • We show that the singular value spectrum can assist in classifying these targets as malignant or benign, especially in the case where contrast-enhanced agents can be employed to allow the analysis of differential backscatter data.
  • [MeSH-major] Algorithms. Breast Neoplasms / diagnosis. Diagnostic Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Microwaves

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21095669.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


53. Petterino C, Ratto A, Arcicasa E, Podestà G, Drigo M, Pellegrino C: Expression of Stat3 in feline mammary gland tumours and its relation to histological grade. Vet Res Commun; 2006 Aug;30(6):599-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Stat3 in feline mammary gland tumours and its relation to histological grade.
  • The samples included 3 normal nonlactating mammary tissues, 17 hyperplastic lesions (11 lobular and 6 fibroepithelial) and 52 neoplasms (5 benign and 47 malignant).
  • [MeSH-major] Cat Diseases / metabolism. Gene Expression Regulation, Neoplastic. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Biomarkers, Tumor / metabolism. Case-Control Studies. Cats. Female. Immunohistochemistry / veterinary. Linear Models. Mitotic Index. Neoplasm Staging / veterinary. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] Breast Cancer Res. 2000;2(2):86-90 [11250696.001]
  • [Cites] J Cell Physiol. 1998 May;175(2):220-8 [9525481.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] Vet J. 2004 Sep;168(2):180-5 [15301767.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2381-7 [9703883.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1385-92 [9769331.001]
  • [Cites] Cell Growth Differ. 1997 Dec;8(12):1267-76 [9419415.001]
  • [Cites] J Virol. 1999 Feb;73(2):1689-94 [9882381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17 ):9148-53 [8799169.001]
  • [Cites] J Virol. 1997 Sep;71(9):6677-82 [9261390.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):840-4 [7710952.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6764-9 [9192639.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5059-63 [10537273.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2553-8 [9566875.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2645-56 [10851064.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):115-27 [11467447.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):978-87 [9041204.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28065-72 [9774423.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):23-8 [10853013.001]
  • [Cites] Blood. 1998 Jan 15;91(2):570-6 [9427711.001]
  • (PMID = 16838202.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


54. Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulić A, Pavelic K, Kapitanovic S: TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol; 2007 Aug;83(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions.
  • The multifunctional cytokine tumor necrosis factor alpha (TNF alpha) has an important role in the pathogenesis of inflammatory, autoimmune and malignant diseases.
  • In recent years, several TNF alpha promoter polymorphisms have been identified and related to the expression level of cytokine and to the susceptibility to solid tumors.
  • The aim of our study was to investigate the frequency of three TNF alpha promoter polymorphisms (-1031, -308 and -238) in benign (fibrocystic changes) and malignant (invasive carcinoma) breast lesions.
  • Using "real-time" PCR SNP analysis these polymorphisms were determined in 76 patients with benign and 158 patients with malignant breast lesions.
  • The high expression genotypes at any of the three SNP polymorphisms were more frequent in invasive breast carcinoma (in 81 of 158 examined, 51.3%) than in fibrocystic changes (in 33 of 76 examined, 43.4%).
  • The combined frequency of high production genotypes (-1031 T/C and C/C, -308 G/A and A/A and -238 G/A and A/A) was higher in patients with invasive breast carcinoma than in those with fibrocystic changes.
  • Further studies on a larger group of patients are needed to evaluate the significance of potential differences in TNF alpha genotypes in different breast lesions.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Fibrocystic Breast Disease / genetics. Fibrocystic Breast Disease / pathology. Polymorphism, Genetic / genetics. Tumor Necrosis Factor-alpha / analysis. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adult. Aged. Alleles. Gene Expression Regulation. Genotype. Humans. Middle Aged. Neoplasm Invasiveness. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234183.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


55. Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW: The molecular signature of metastases of human hepatocellular carcinoma. Oncology; 2005;69 Suppl 1:23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current metastasis paradigm suggests that the primary tumor starts off benign but over time slowly acquires changes that provide a few rare cells within the tumor the ability to metastasize.
  • Similar findings are also evident in primary cancers of the lung, breast, and prostate.
  • These findings imply that many of the metastasis-promoting genes are embedded in the primary tumors and that the ability to metastasize may be an inherent quality of the tumor from the beginning.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Neoplasm Metastasis / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Gene Expression Profiling. Humans. Models, Biological. Osteopontin. Prognosis. Sialoglycoproteins / analysis. Sialoglycoproteins / physiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210873.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  • [Number-of-references] 21
  •  go-up   go-down


56. Fortunato L, Penteriani R, Farina M, Vitelli CE, Piro FR: Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors. Eur J Surg Oncol; 2008 Dec;34(12):1289-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors.
  • INTRODUCTION: Non-palpable breast tumors represent an increasing management problem in modern Breast Units.
  • METHODS: We conducted a prospective study on patients with malignant or benign non-palpable breast tumors who were surgically treated and underwent intraoperative ultrasound (IOUS) from May 2006 to June 2007.
  • RESULTS: There were 77 patients (60 malignant and 17 benign lesions), with a median age of 54 years (36-87), and a median diameter of 9mm (4-17).
  • In the remaining cases, the median distance from the tumor to the closest margins of excision, with exclusion of the posterior (fascial) and anterior (skin) margins, was 1.3cm (0.3-3.2).
  • CONCLUSIONS: IOUS is a simple and accurate procedure that can be used to identify most non-palpable breast tumors, and has many advantages over the more commonly used wire-localization technique.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Intraoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Palpation. Prospective Studies. Reproducibility of Results. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248946.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


57. Clarke LE, Seykora JT: Primary cutaneous adenomyoepithelioma. J Cutan Pathol; 2007 Aug;34(8):654-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 83-year-old Caucasian woman presented to her dermatologist with a 5-cm subcutaneous tumor on her right thigh.
  • Incisional biopsy showed a multinodular tumor composed of variably sized glands comprised of a luminal layer of epithelial cells surrounded by one or more layers of myoepithelial cells.
  • The histopathologic features resembled those of adenomyoepithelioma, an uncommon neoplasm usually encountered within the breast.
  • Primary cutaneous adenomyoepithelioma is very rare yet shares histopathologic features with common cutaneous lesions such as spiradenomas and benign mixed tumors (chondroid syringomas).
  • Primary cutaneous adenomyoepithelioma is part of the spectrum of epithelial-myoepithelial tumors that includes benign mixed tumor, myoepithelioma and myoepithelial carcinoma.
  • This rare tumor may mimic malignant lesions including metastatic adenocarcinoma.
  • Like its breast counterpart, primary cutaneous adenomyoepithelioma should probably be regarded as a neoplasm of borderline malignant potential.
  • [MeSH-major] Adenomyoma / pathology. Myoepithelioma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640238.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Ren Y, Wu L, Frost AR, Grizzle W, Cao X, Wan M: Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer. Mol Cancer; 2009 Nov 27;8:111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer.
  • BACKGROUND: TGF-beta resistance often develops in breast cancer cells that in turn overproduce this cytokine to create a local immunosuppressive environment that fosters tumor growth and exacerbates the invasive and metastatic behavior of the tumor cells themselves.
  • Smads-mediated cross-talk with the estrogen receptor has been implied to play an important role in development and/or progression of breast cancer.
  • We investigated how TGF-beta regulates ERalpha-induced gene transcription and potential mechanisms of frequent TGF-beta resistance in breast cancer.
  • METHODS: Effect of TGF-beta on ERalpha-mediated gene transcription was investigated in breast cancer cell lines using transient transfection, real-time PCR, sequential DNA precipitation, and small interfering RNA assays.
  • The expression of Smads on both human breast cancer cell lines and ERalpha-positive human breast cancer tissue was evaluated by immunofluorescence and immunohistochemical assays.
  • RESULTS: A complex of Smad3/4 mediates TGF-beta inhibition of ERalpha-mediated estrogenic activity of gene transcription in breast cancer cells, and Smad4 is essential and sufficient for such repression.
  • Down-regulation and abnormal cellular distribution of Smad4 were associated with some ERalpha-positive infiltrating human breast carcinoma.
  • There appears a dynamic change of Smad4 expression from benign breast ductal tissue to infiltrating ductal carcinoma.
  • CONCLUSION: These results suggest that aberrant expression of Smad4 or disruption of Smad4 activity lead to the loss of TGF-beta suppression of ERalpha transactivity in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2008 Apr;32(4):791-6 [18360706.001]
  • [Cites] Breast Cancer Res. 2007;9(4):305 [17705882.001]
  • [Cites] Cell Oncol. 2008;30(4):337-47 [18607068.001]
  • [Cites] Cells Tissues Organs. 2008;188(1-2):225-35 [18303245.001]
  • [Cites] Hum Mutat. 2009 Feb;30(2):E451-9 [19058223.001]
  • [Cites] Breast Cancer Res. 2009;11(1):202 [19291273.001]
  • [Cites] Exp Mol Pathol. 2009 Aug;87(1):48-53 [19341727.001]
  • [Cites] Nat Cell Biol. 2001 Jun;3(6):587-95 [11389444.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42908-14 [11555647.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2635-42 [12072396.001]
  • [Cites] Cell. 2002 Jul 12;110(1):19-32 [12150994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15192-200 [12576474.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):799-804 [12821112.001]
  • [Cites] Development. 2003 Dec;130(24):6143-53 [14597578.001]
  • [Cites] Mol Endocrinol. 2004 Jul;18(7):1643-57 [15056732.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):299-303 [2295070.001]
  • [Cites] Mol Cell Endocrinol. 1993 Nov;97(1-2):115-23 [8143893.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):513-29 [7844613.001]
  • [Cites] J Cell Biochem. 1996 Apr;61(1):9-17 [8726350.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7749-56 [9516484.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):98-103 [10077159.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4879-83 [10490821.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):937s-43s [15701890.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):372-83 [15645498.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R753-64 [16168121.001]
  • [Cites] JAMA. 2005 Oct 5;294(13):1634-46 [16204663.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:659-93 [16212511.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3044-50 [16540653.001]
  • [Cites] BMC Cancer. 2006;6:25 [16438724.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):601-7 [16627986.001]
  • [Cites] Hum Mutat. 2006 Sep;27(9):897-905 [16865698.001]
  • [Cites] Cell Biochem Biophys. 2006;46(1):79-90 [16943625.001]
  • [Cites] Carcinogenesis. 2006 Nov;27(11):2148-56 [16698802.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):433-42 [17167985.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:119-26 [17261761.001]
  • [Cites] J Pathol. 2007 Apr;211(5):499-506 [17236182.001]
  • [Cites] Nat Genet. 2007 May;39(5):655-60 [17417639.001]
  • [Cites] Front Biosci. 2007;12:4393-401 [17485383.001]
  • [Cites] Exp Mol Pathol. 2007 Jun;82(3):284-91 [17289018.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):905-31 [17615392.001]
  • [Cites] Prostate. 2008 May 1;68(6):661-74 [18213629.001]
  • (PMID = 19943940.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK60913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Smad3 Protein; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2787496
  •  go-up   go-down


59. Zhang JJ, Ouyang T, Wan WH, Deng GR: [Detection of free tumor-related DNA in the serum of breast cancer patients]. Zhonghua Zhong Liu Za Zhi; 2007 Aug;29(8):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free tumor-related DNA in the serum of breast cancer patients].
  • OBJECTIVE: To study the APC and E-cadherin gene promoter hypermethylation as tumor marker and to investigate the correlation of free tumor-related DNA in serum and tumor tissue with clinicopathological parameters.
  • Their feasibility in early diagnosis, predicting therapeutic effect and monitoring recurrence was evaluated.
  • METHODS: 84 cases with operated breast cancer were recruited from March 2002 to August 2002 at Beijing Cancer Hospital.
  • Aberrant methylation of E-cadherin and APC genes was detected in tumor tissues, adjacent normal tissues and peripheral blood serum by methylation-specific PCR (MSP).
  • 10 cases with benign breast diseases were selected as control group.
  • RESULTS: The positive rate of promoter hypermethylation of E-cadherin and APC genes in tumor tissues was 52.4% and 45.2%, in the paired serum was 33.3% and 31.0%, respectively.
  • Aberrant methylation of free DNA in serum presented the same alteration in tumor tissues.
  • E-cadherin and APC hypermethylation in serum and tumor samples significantly correlated each other (E-cadherin P < 0.001; APC P = 0.002).
  • There was no correlation for the aberrant methylation in cancer tissues and serum with the clinicopathological parameters of patients including age, tumor staging, tumor size, histological type and receptor.
  • CONCLUSION: The same aberrant methylation in cancer tissues and serum, not correlating with tumor staging, can be detected in about one third of breast cancer patients.
  • The results imply that this approach may be feasible for early diagnosis, evaluation of therapeutic effects and monitoring recurrence of breast cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Cadherins / genetics. DNA Methylation. DNA, Neoplasm / blood. Genes, APC. Genes, Tumor Suppressor
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. CpG Islands. Female. Humans. Middle Aged. Promoter Regions, Genetic. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210882.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA, Neoplasm
  •  go-up   go-down


60. Gustafson S, Zbuk KM, Scacheri C, Eng C: Cowden syndrome. Semin Oncol; 2007 Oct;34(5):428-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cowden syndrome (CS), due to germline mutations of the PTEN tumor-suppressor gene, is an often overlooked cancer predisposition syndrome associated with an increased risk of breast, thyroid, and endometrial cancers, as well as benign manifestations.
  • These syndromes can be described under the umbrella of PTEN hamartoma tumor syndrome (PHTS).

  • Genetic Alliance. consumer health - Cowden Syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920899.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 40
  •  go-up   go-down


61. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP, National Academy of Clinical Biochemistry: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem; 2008 Dec;54(12):e11-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
  • BACKGROUND: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.
  • METHODS: Published reports relevant to use of tumor markers for 5 cancer sites--testicular, prostate, colorectal, breast, and ovarian--were critically reviewed.
  • RESULTS: For testicular cancer, alpha-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. alpha-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors.
  • Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 microg/L.
  • For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node-negative patients.
  • CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.
  • CONCLUSIONS: Implementation of these recommendations should encourage optimal use of tumor markers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Clinical Laboratory Techniques. Colorectal Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Testicular Neoplasms / diagnosis


62. Mottolese M, Nádasi EA, Botti C, Cianciulli AM, Merola R, Buglioni S, Benevolo M, Giannarelli D, Marandino F, Donnorso RP, Venturo I, Natali PG: Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer. J Cell Physiol; 2005 Jul;204(1):106-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer.
  • To determine whether phenotypic field changes occur in tissues adjacent to carcinoma, we assayed, by immunohistochemistry, the expression of HER-2, p53, Fas, and FasL in 72 breast cancers (BC) and multiple autologous peritumoral tissues (PTTs) sampled up to 5 cm distance and in 44 benign breast tumors (BBTs).
  • Our data suggest that FasL could be a potential novel biomarker of transformation, which may identify, along with HER2 and p53, precursor lesions in a genetically altered breast tissue.
  • [MeSH-major] Antigens, CD95 / metabolism. Breast / metabolism. Breast Neoplasms / metabolism. Membrane Glycoproteins / metabolism. Receptor, ErbB-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Breast Diseases / metabolism. Breast Diseases / pathology. Early Diagnosis. Fas Ligand Protein. Female. Humans. Immunohistochemistry. Phenotype

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15622519.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


63. Tumminello FM, Flandina C, Crescimanno M, Leto G: Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed Pharmacother; 2008 Feb;62(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM).
  • In PCa patients, cathepsin K concentrations did not significantly differ from those measured in sex matched HS or in patients with benign prostatic hyperplasia (BPH).
  • [MeSH-major] Biomarkers, Tumor / blood. Bone Neoplasms / secondary. Cathepsins / blood. Cystatins / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Density Conservation Agents / pharmacology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Case-Control Studies. Cathepsin K. Cystatin C. Diphosphonates / pharmacology. Disease Progression. Drug Monitoring / methods. Enzyme-Linked Immunosorbent Assay. Female. Humans. Imidazoles / pharmacology. Male. Middle Aged. Osteoporosis / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. ROC Curve

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728092.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
  •  go-up   go-down


64. Fine RE, Staren ED: Percutaneous radiofrequency-assisted excision of fibroadenomas. Am J Surg; 2006 Oct;192(4):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Fibroadenomas are a frequently encountered benign tumor that will occur in approximately 10% of women during their lifetime.
  • METHODS: Between April 2004 and November 2005, 100 patients underwent ultrasound- or stereotactic-guided, radiofrequency-assisted intact percutaneous excision of 106 diagnosed fibroadenomas of the breast.
  • On pathologic examination, the tumors ranged in size from 6 to 27 mm (mean diameter, 14 mm) and weighed from 0.6 to 2.0 g (mean weight, 1.0 g).
  • CONCLUSIONS: Percutaneous ultrasound- or stereotactic-guided, radiofrequency-assisted excision of fibroadenomas of the breast may be performed in an ambulatory setting under local anesthesia.
  • [MeSH-major] Breast Neoplasms / surgery. Electrosurgery / instrumentation. Fibroadenoma / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978972.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Schor AP, Carvalho FM, Kemp C, Silva ID, Russo J: S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep; 2006 Jan;15(1):3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.
  • Benign breast diseases represent the vast majority of diagnosis in breast pathology.
  • However, the limited capability in identifying lesions at high risk of breast cancer evolution is an increasing problem in clinical practice.
  • In the present study, we tested the hypothesis that the overexpression of S100P calcium-binding protein, previously identified in the very early stages of breast carcinogenesis, could be used as a marker to differentiate lesions at high risk of malignant evolution.
  • In addition to S100P, the well-known proliferative marker, Ki-67, and estrogen receptor (ER) status were also assessed by immunohistochemistry in 155 samples from patients who submitted to stereotactic vacuum-assisted core biopsy due to breast microcalcifications.
  • The strong association between S100P and ER expression highlights the hypothesis about the possible role played by S100P in the very early stages of breast carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Diseases / pathology. Breast Neoplasms / diagnosis. Calcium-Binding Proteins / metabolism. Neoplasm Proteins / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328027.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / S100P protein, human
  •  go-up   go-down


66. Huang SF, Chang RF, Moon WK, Lee YH, Chen DR, Suri JS: Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images. IEEE Trans Med Imaging; 2008 Mar;27(3):320-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images.
  • Tumor vascularity is an important factor that has been shown to correlate with tumor malignancy and was demonstrated as a prognostic indicator for a wide range of cancers.
  • Three-dimensional (3-D) power Doppler ultrasound (PDUS) offers a convenient tool for investigators to inspect the signals of blood flow and vascular structures in breast cancer.
  • In this paper, a new computer-aided diagnosis (CAD) system for quantifying Doppler ultrasound images based on 3-D thinning algorithm and neural network is proposed.
  • Benign and malignant tumors can therefore be differentiated by a score computed by a multilayered perceptron (MLP) neural network using these features as parameters.
  • The proposed system was tested on 221 breast tumors, including 110 benign and 111 malignant lesions.
  • The results demonstrate a correlation between the morphology of blood vessels and tumor malignancy, indicating that the newly proposed method can retrieves a high accuracy in the classification of benign and malignant breast tumors.
  • [MeSH-major] Algorithms. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Neoplasms / blood supply. Neoplasms / ultrasonography. Neovascularization, Pathologic / ultrasonography. Ultrasonography, Doppler / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334428.001).
  • [ISSN] 0278-0062
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Aged. Gene Expression. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / genetics. RNA, Neoplasm / genetics


68. Niedźwiecki S, Stepień T, Kuzdak K, Stepień H, Krupiński R, Seehofer D, Rayes N, Ulrich F: Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg; 2008 May;393(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We measured preoperative IL-1ra serum levels of 52 consecutive patients with thyroid cancer, 15 with benign adenoma and 27 healthy volunteers.
  • The final histological diagnosis revealed 21 patients with papillary and 8 patients with follicular carcinoma (FTC), while 12 cases of medullary and 11 cases of anaplastic carcinoma (ATC) were observed.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin 1 Receptor Antagonist Protein / blood. Thyroid Neoplasms / blood

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Langenbecks Arch Surg. 2009 Mar;394(2):401-2; author reply 403 [18825404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13 [8855299.001]
  • [Cites] Lancet. 1987 Nov 28;2(8570):1240-2 [2890857.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):197-202 [16319982.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1501-4 [14504049.001]
  • [Cites] Am J Med. 1990 Nov;89(5):621-9 [2239982.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4218-23 [1836481.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):794-803 [8362978.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Dec;104(12):1407-8 [9422021.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):132-8 [8173722.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1139-43 [10582766.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):269-75 [1531398.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):179-84 [10463774.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1667-74 [17138728.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):395-405 [17593869.001]
  • [Cites] J Biol Chem. 1991 Jun 5;266(16):10331-6 [1828071.001]
  • [Cites] Blood. 1992 May 1;79(9):2196-200 [1533321.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1627-52 [1826616.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1738-43 [7908231.001]
  • [Cites] Arthritis Rheum. 1995 Aug;38(8):1055-9 [7639800.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1863-74 [10377182.001]
  • [Cites] Annu Rev Immunol. 1998;16:27-55 [9597123.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):2930-40 [9185517.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Apr;31(4):719-24 [17317198.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):161-4 [1832651.001]
  • [Cites] Scand J Immunol. 1998 Mar;47(3):195-8 [9519856.001]
  • [Cites] J Soc Gynecol Investig. 2002 Nov-Dec;9(6):386-90 [12445604.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2339-45 [15800325.001]
  • [Cites] J Immunol. 1993 May 1;150(9):4008-18 [8473746.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):204-9 [11740709.001]
  • [Cites] Eur Cytokine Netw. 1994 Nov-Dec;5(6):517-31 [7727685.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):493-7 [16106254.001]
  • [Cites] Prog Growth Factor Res. 1990;2(4):193-205 [2151936.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3282-8 [8605344.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):303-10 [7851026.001]
  • [Cites] Gastric Cancer. 2006;9(4):284-90 [17235630.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1251-4 [10568836.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):968 [1357359.001]
  • [Cites] Pharmacol Res. 2007 Feb;55(2):131-8 [17174563.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Mar;27(3):387-9 [17426001.001]
  • [Cites] Arthritis Rheum. 1994 Dec;37(12):1744-51 [7986220.001]
  • (PMID = 18064485.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein
  •  go-up   go-down


69. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G: Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate; 2005 Feb 15;62(3):224-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human protectin (CD59) is a regulator of complement activation that inhibits complement-mediated cell lysis, and thus might confer immune resistance to tumor cells.
  • CD59 expression has been described in a variety of human malignancies, including breast cancer.
  • The immunoreactivity of the tumor was evaluated as low versus high for statistical analysis.
  • Additionally, CD59 mRNA levels were determined by real-time PCR in matched (tumor/normal) microdissected tissues from 26 cases.
  • RESULTS: Cytoplasmic CD59 immunoreactivity was found in epithelia of prostate cancer, prostatic intraepithelial neoplasia, benign hyperplasia, atrophic, and normal glands.
  • High rates of CD59 expression were noted in 36% of prostate cancer cases and were significantly associated with tumor pT stage (P = 0.043), Gleason grade (P = 0.013) and earlier biochemical (PSA) relapse in Kaplan-Meier analysis (P = 0.0013).
  • On RNA level, we found an upregulation in 19.2% (five cases), although the general rate of CD59 transcript was significantly lower in tumor tissue (P = 0.03).
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD59 / biosynthesis. Neoplasm Recurrence, Local / immunology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / immunology


70. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • The six malignancies consisted of carcinoma of the breast in two patients, and carcinoma of the orbit, esophagus, prostate, and non-Hodgkin's lymphoma in one patient each.
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Popnikolov NK, Cavone SM, Schultz PM, Garcia FU: Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells. Mod Pathol; 2005 Dec;18(12):1535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • We evaluated the low affinity neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
  • Immunohistochemical staining for p75NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue.
  • The staining pattern was compared to those of myosin heavy chain and p63. p75NTR immunostain was consistently positive and compatible with p63 and myosin immunoreactivity in the myoepithelial cells of the normal mammary gland, benign breast lesions (six usual ductal hyperplasias, six specimens with sclerosing adenosis, eight intraductal papillomas, six fibroadenomas), and carcinoma in situ (18 ductal carcinomas in situ, two noninvasive papillary carcinomas, two lobular carcinomas in situ).
  • No myosin immunoreactivity was seen in the luminal/tumor cells, but p63 pattern of staining in the luminal/tumor cells was quite similar to that of p75NTR.
  • Our study shows that p75NTR is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease as well as to evaluate difficult for diagnosis sclerosing lesions.
  • Our data suggest a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast / pathology. Breast Neoplasms / pathology. Epithelial Cells / pathology. Muscle, Smooth / pathology. Receptor, Nerve Growth Factor / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Immunoenzyme Techniques. Myosin Heavy Chains / metabolism. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258511.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


72. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P, Benign Breast Diseases Study Group: Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A; 2008 Sep 23;105(38):14533-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors.
  • Given the essential role of this hormonal system in breast physiology, we reasoned that genetic anomalies of Prl/PrlR genes may be related to the occurrence of breast diseases with high proliferative potential.
  • Multiple fibroadenomas (MFA) are benign breast tumors which appear most frequently in young women, including at puberty, when Prl has well-recognized proliferative actions on the breast.
  • Constitutive activity of PrlR(I146L) in the breast sample from a patient was supported by increased STAT5 signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Fibroadenoma / genetics. Fibroadenoma / metabolism. Mutation, Missense. Receptors, Prolactin / genetics. Receptors, Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Guide to Pharmacology. gene/protein/disease-specific - Prolactin-releasing peptide receptor - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - PrRP receptor - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):665-71 [14696092.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4056-66 [16809439.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(6):483-8 [3321867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4031-5 [7537382.001]
  • [Cites] Mol Endocrinol. 1996 Jan;10(1):45-56 [8838144.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29707-14 [8939904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):989-1008 [17138649.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):841-4 [17299388.001]
  • [Cites] BMC Med Genet. 2007;8:72 [18053149.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3826-32 [11502819.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Endocrine. 2003 Feb-Mar;20(1-2):177-90 [12668884.001]
  • [Cites] Recent Prog Horm Res. 2003;58:297-323 [12795425.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):35988-99 [12824168.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10024-34 [10187780.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] N Engl J Med. 2005 Jul 21;353(3):275-85 [16034013.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):555-62 [16278261.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1513-9 [16434456.001]
  • [Cites] J Endocrinol. 2006 Aug;190(2):271-85 [16899561.001]
  • [Cites] Biol Reprod. 2004 Mar;70(3):718-28 [14613905.001]
  • (PMID = 18779591.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Receptors, Prolactin; 0 / STAT5 Transcription Factor; 0 / Tyrphostins; 0 / alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
  • [Other-IDs] NLM/ PMC2567233
  • [Investigator] Bachelot A; Belaroussi B; Bensimhon J; Berdah J; Blin MJ; Boudinet A; Brethon B; Bricaire C; Caby J; Caillaud G; Carel JC; Chabbert-Buffet N; Charitanski H; Chretien C; Clough K; Courtillot C; Delattre G; Denys I; Desthieux-Ngo K; Detoeuf M; Dhainault C; Duflos C; Fiori O; Genestie C; Gibaud G; Gompel A; Gracia C; Grimard A; Hofman C; Hofman H; Kuttenn F; Laki F; Lanty C; Lefranc JP; Le Frere-Belda MA; Leger D; Martinez F; May A; Meng L; Nos C; Pelletier D; Perrin A; Plu-Bureau G; Raccah-Tebbeca B; Saiovici JC; Salmon R; Sibout M; Sigal-Zafrani B; Thalabard JC; Thibaud E; Thoury A; Touraine P; Triana-Rabi KB; Uzan S; Viriot J; Yacoub S
  •  go-up   go-down


73. Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, Ando M, Katsumata N, Fujiwara Y: Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathol Res Pract; 2006;202(10):705-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
  • Phyllodes tumors are rare primary tumors of the breast.
  • The study aimed at evaluating the immunohistochemical features of phyllodes tumors of the breast that may be useful for predicting the clinical outcome.
  • The study included 41 patients with phyllodes tumor (20 benign, 5 borderline, and 16 malignant).
  • None of the phyllodes tumors was positive for HER2/neu or CD117/c-kit.
  • Positive staining for p53 was seen in 10 phyllodes tumors (24%), and the median MIB-1 index was 10%.
  • Both p53 expression and the MIB-1 index, but not the expression status of EGFR, were significantly correlated with the recurrence-free and overall survival. p53 expression status and MIB-1 index may be significant prognostic factors in patients with phyllodes tumors, and careful postoperative follow-up may be important in those cases showing positive expression of p53 and/or MIB-1 index.
  • [MeSH-major] Breast Neoplasms / metabolism. Ki-67 Antigen / metabolism. Phyllodes Tumor / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local. Survival Rate


74. Spanu A, Chessa F, Meloni GB, Sanna D, Cottu P, Manca A, Nuvoli S, Madeddu G: The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer. Clin Nucl Med; 2008 Nov;33(11):739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer.
  • Planar scintimammography (SM) acquired with a conventional gamma camera has proved a useful complementary tool to mammography (Mx) in breast cancer (BC) diagnosis, but with unsatisfactory sensitivity in small size carcinomas.
  • In this study we assessed the role of planar SM with a high-resolution dedicated breast camera (DBC) in BC diagnosis, comparing the results with those of Mx.A consecutive series of 145 patients scheduled for biopsy for suspected BC underwent Tc-99m tetrofosmin planar SM using a newly developed DBC.
  • Scintigraphic data were compared with Mx findings and correlated to histology.Histopathologic analysis revealed 165 lesions: 143 malignant and 22 benign.
  • SM detected 139/143 carcinomas (overall sensitivity: 97.2%) and was true negative in 19/22 benign lesions (overall specificity: 86.4%).
  • SM was more accurate than Mx in 42/145 cases (29%), detecting cancer in 9 patients with Mx indeterminate for dense breasts (8/9 tumors were <10 mm), assessing additional tumor foci (all <10 mm) in 5 points with multifocal disease and correctly classifying 28 patients with inconclusive mammographic findings as affected by cancer or by benign disease.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Gamma Cameras. Mammography / instrumentation. Radionuclide Imaging / instrumentation

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - Nuclear Scans.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936602.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


75. Pathak P, Prasad GL, Meziani MJ, Joudeh AA, Sun YP: Nanosized paclitaxel particles from supercritical carbon dioxide processing and their biological evaluation. Langmuir; 2007 Feb 27;23(5):2674-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rapid expansion of a supercritical solution into a liquid solvent (RESOLV) technique with benign supercritical carbon dioxide was applied to obtain aqueous suspended nanoparticles of the highly potent anticancer drug paclitaxel.
  • The aqueous suspended paclitaxel nanoparticles of different average particle sizes were evaluated in vitro against human breast cancer cells.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor. Flow Cytometry. Humans. Microscopy, Confocal. Microscopy, Electron, Scanning. Solubility. Solvents / chemistry. Time Factors. X-Ray Diffraction

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243738.001).
  • [ISSN] 0743-7463
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Solvents; 142M471B3J / Carbon Dioxide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


76. Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C: Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol; 2007 Oct;17(10):2646-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion.
  • The role of diffusion-weighted magnetic resonance imaging (DWI) to differentiate breast lesions in vivo was evaluated.
  • Sixty women (mean age, 53 years) with 81 breast lesions were enrolled.
  • Differences in MD among cysts, benign lesions and malignant lesions were evaluated, and the sensitivity and specificity of DWI to diagnose malignant and benign lesions were calculated.
  • The diagnosis was 18 cysts, 21 benign and 42 malignant nodules.
  • MD values (mean +/- SD x 10(-3) mm(2)/s) were (1.48 +/- 0.37) for benign lesions, (0.95 +/- 0.18) for malignant lesions and (2.25 +/- 0.26) for cysts.
  • Different MD values characterized different malignant breast lesion types.
  • A MD threshold value of 1.1 x 10(-3) mm(2)/s discriminated malignant breast lesions from benign lesions with a specificity of 81% and sensitivity of 80%.
  • Thus, MD values, related to tumor cellularity, provide reliable information to differentiate malignant breast lesions from benign ones.
  • Quantitative DWI is not time-consuming and can be easily inserted into standard clinical breast MR imaging protocols.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Humans. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] NMR Biomed. 2001 Apr;14(2):77-93 [11320535.001]
  • [Cites] Radiology. 2003 Jan;226(1):153-60 [12511684.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] J Magn Reson Imaging. 2002 Jun;15(6):693-704 [12112520.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1257-62 [10789773.001]
  • [Cites] JAMA. 1987 May 8;257(18):2459-63 [3573245.001]
  • [Cites] Radiology. 2005 Oct;237(1):45-56 [16126926.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Eur Radiol. 2005 Sep;15(9):2010-7 [15841382.001]
  • [Cites] Eur Radiol. 2005 Nov;15(11):2268-75 [16012822.001]
  • [Cites] Radiology. 2006 Mar;238(3):801-8 [16424237.001]
  • [Cites] Radiology. 2001 May;219(2):484-94 [11323476.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):456-67 [12489095.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):534-46 [11276097.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] Radiology. 2001 Dec;221(3):650-5 [11719659.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):543-52 [12489100.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):959-65 [11906883.001]
  • [Cites] NMR Biomed. 1997 Oct;10(7):348-52 [9471126.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6 [12488758.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 2005 Jan;65(1):30-6 [15726897.001]
  • [Cites] J Mal Vasc. 1995;20(3):203-14 [8543902.001]
  • [Cites] Radiology. 2004 Jul;232(1):221-8 [15220505.001]
  • [Cites] Clin Radiol. 2005 Mar;60(3):375-83 [15710142.001]
  • [Cites] Eur Radiol. 2005 Jul;15(7):1353-60 [15789211.001]
  • [Cites] Radiology. 2004 Aug;232(2):585-91 [15205478.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Ann Surg. 1951 Jan;133(1):18-36 [14800254.001]
  • [Cites] J Magn Reson B. 1994 Mar;103(3):247-54 [8019776.001]
  • [Cites] J Magn Reson Imaging. 2006 Sep;24(3):478-88 [16897692.001]
  • [Cites] J Magn Reson Imaging. 2001 Oct;14(4):433-8 [11599068.001]
  • [Cites] NMR Biomed. 2002 Nov-Dec;15(7-8):435-55 [12489094.001]
  • [Cites] Radiology. 2005 Oct;237(1):258-64 [16183935.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):331-7 [9930777.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):52-6 [16434586.001]
  • (PMID = 17356840.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G: The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol; 2009 Jan-Feb;27(1):53-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To improve treatment for patients with breast and prostate cancer.
  • Aromatase (estrogen synthetase) inhibitors have now been extensively tested in clinical trials in breast cancer patients.
  • Inhibitors of aromatase (AIs) are showing greater benefit than antiestrogens in the treatment of breast cancer.
  • Although effective in other conditions in both women and men, AIs have not been useful in benign prostatic hypertrophy or prostate cancer.
  • However, inevitably tumors eventually began to grow despite continued treatment.
  • Analysis of breast tumors from mice treated with letrozole revealed up-regulation of HER-2 and MAP Kinase signaling proteins and down-regulation of the estrogen receptor.
  • Our studies showed that tumors adapt to AI treatment by activating alternate signaling pathways, thus enabling them to proliferate in the absence of estrogen.
  • When mice bearing resistant tumors were treated with trastuzumab, the anti-HER-2 antibody (herceptin), HER-2 was decreased in the tumor but the estrogen receptor and aromatase were restored.
  • Tumor growth was significantly inhibited by treatment with trastuzumab in addition to letrozole.
  • CONCLUSIONS: Aromatase inhibitors are proving to be an effective new class of agents for the treatment of breast cancer.
  • Our results suggest that strategies to overcome resistance to these types of agents can restore sensitivity of the tumors to hormone therapy.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 1987 Oct-Dec;50(4-6):523-36 [3332939.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):622-30 [10574247.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):461-8 [2465302.001]
  • [Cites] N Engl J Med. 1989 Aug 17;321(7):419-24 [2503724.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6551-5 [2479464.001]
  • [Cites] Biol Reprod. 1989 Nov;41(5):889-98 [2696557.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6949-54 [2208160.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):717-26 [1890148.001]
  • [Cites] Ann Med. 1991 Aug;23(3):201-3 [1718322.001]
  • [Cites] Gynecol Endocrinol. 1992 Mar;6(1):13-7 [1580162.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1247-52 [1592866.001]
  • [Cites] Cancer. 1993 Feb 1;71(3 Suppl):1059-67 [8428328.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):321-30 [8476746.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Apr;45(4):217-25 [8499330.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2861-4 [8187068.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1995;35:195-211 [7598491.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):3073-7 [7606729.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):3061-8 [8770932.001]
  • [Cites] Prostate. 1996 Sep;29(3):153-8 [8827083.001]
  • [Cites] J Urol. 1997 Apr;157(4):1204-7 [9120902.001]
  • [Cites] Drugs Aging. 1997 Jan;10(1):50-8 [9111707.001]
  • [Cites] J Med Chem. 1998 Mar 12;41(6):902-12 [9526564.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13317-23 [9582378.001]
  • [Cites] Curr Pharm Des. 1999 Mar;5(3):163-80 [10066888.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s [15701882.001]
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2972-84 [15828836.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5380-9 [15958587.001]
  • [Cites] Curr Med Chem. 2005;12(14):1623-9 [16022662.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1241-6 [16287438.001]
  • [Cites] Minerva Endocrinol. 2006 Mar;31(1):1-12 [16498360.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Pharmacol Ther. 2006 Jul;111(1):27-52 [16426683.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5033-41 [17510436.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):301-6 [17387321.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2348-57 [18723482.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1416-28 [19190349.001]
  • [Cites] Br J Cancer. 2010 Sep 28;103(7):1001-7 [20842117.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6630-40 [11118046.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2095-101 [11596025.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7 [11850206.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • [Cites] Arch Pharm (Weinheim). 2002 Apr;335(4):119-28 [12112031.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2378-88 [12114443.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4921-31 [12118371.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1864-8 [12404279.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 [12529347.001]
  • [Cites] Mol Endocrinol. 2003 Mar;17(3):309-17 [12554774.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):245-54 [12954493.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):456-65 [15026471.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2317-25 [15150570.001]
  • [Cites] J Clin Endocrinol Metab. 1973 Feb;36(2):207-14 [4688315.001]
  • [Cites] Endocrinology. 1973 Mar;92(3):866-80 [4267111.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Mar;38(3):476-9 [4815174.001]
  • [Cites] Endocrinology. 1977 Jun;100(6):1684-95 [404132.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Jan;46(1):146-52 [752017.001]
  • [Cites] Cancer Res. 1982 Aug;42(8 Suppl):3365s-3368s [7083201.001]
  • [Cites] Cancer Res. 1982 Aug;42(8 Suppl):3369s-3372s [7083202.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Apr;18(4):333-7 [6889509.001]
  • [Cites] Prostate. 1982;3(5):433-8 [6183651.001]
  • [Cites] J Urol. 1984 Jul;132(1):61-3 [6328052.001]
  • [Cites] J Urol. 1984 Oct;132(4):693-6 [6471215.001]
  • [Cites] Lancet. 1984 Dec 1;2(8414):1237-9 [6150277.001]
  • [Cites] Br J Urol. 1986 Feb;58(1):45-51 [3947856.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4823-6 [2942241.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):779-82 [3802035.001]
  • [Cites] Prostate. 1987;11(4):313-26 [2446299.001]
  • [Cites] Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):741-3 [3126957.001]
  • [Cites] Steroids. 1987 Jul-Sep;50(1-3):269-79 [3509763.001]
  • (PMID = 19111799.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA027440; United States / NCI NIH HHS / CA / R01 CA062483-28W1; United States / NCI NIH HHS / CA / R01 CA027440-23; United States / NCI NIH HHS / CA / CA-62483; United States / NCI NIH HHS / CA / CA062483-28W1; United States / NCI NIH HHS / CA / CA027440-23; United States / NCI NIH HHS / CA / R01 CA062483
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Steroids; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; EC 1.14.14.1 / Aromatase; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Number-of-references] 80
  • [Other-IDs] NLM/ NIHMS88209; NLM/ PMC3090255
  •  go-up   go-down


78. Kushlinskii NE, Shirokii VP, Gershtein ES, Yermilova VD, Chemeris GY, Letyagin VP: Soluble fragment of HER2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor. Bull Exp Biol Med; 2007 Apr;143(4):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble fragment of HER2/neu receptor in the serum of patients with breast cancer with different levels of this protein expression in the tumor.
  • Serum level of soluble HER2/neu in patients with tumors characterized by high expression of this protein (2+/3+ according to immunohistochemical analysis) was significantly higher than in patients with low expression of HER2/neu and in women with benign diseases of the mammary glands.
  • The level of HER2/neu in the serum decreased after removal of the primary tumor in the majority of patients.
  • [MeSH-major] Breast Neoplasms / blood. Receptor, ErbB-2 / blood
  • [MeSH-minor] Breast / chemistry. Breast / pathology. Breast / surgery. Breast Diseases / blood. Breast Diseases / metabolism. Breast Diseases / pathology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18214297.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


79. Chung EM, Cube R, Hall GJ, González C, Stocker JT, Glassman LM: From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation. Radiographics; 2009 May-Jun;29(3):907-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.
  • The spectrum of breast lesions in children and adolescents varies markedly from that for adults, with the former lesions being overwhelmingly benign.
  • A breast mass in a young boy or girl may arise from normal and abnormal breast development.
  • After onset of puberty, most cases of breast enlargement arise from benign fibroadenoma in girls and gynecomastia in boys.
  • These conditions have specific imaging appearances, although juvenile (often giant) fibroadenoma cannot be distinguished from phyllodes tumor, which can be benign or malignant.
  • A diagnosis of juvenile papillomatosis (a benign lesion) portends later development of breast cancer, and patients with this condition should be closely monitored.
  • Malignant lesions of the breast in children are rare.
  • The most common primary breast malignancy is malignant phyllodes tumor.
  • Primary breast carcinoma is exceedingly rare in the pediatric age group, but its imaging appearance in children is the same as seen in adults and is different from that of almost all benign lesions.
  • In girls, diagnostic interventions may injure the developing breast and cause subsequent disfigurement.
  • Given this risk and the low prevalence of malignant disease in this population, a prudent course should be followed in the diagnosis of breast lesions.
  • [MeSH-major] Breast Diseases / radiography
  • [MeSH-minor] Adolescent. Breast / abnormalities. Breast / anatomy & histology. Breast / growth & development. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / radiography. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Breast Neoplasms, Male / secondary. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / radiography. Carcinoma, Ductal, Breast / ultrasonography. Child. Child, Preschool. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fibroadenoma / radiography. Granular Cell Tumor / diagnosis. Granular Cell Tumor / pathology. Granular Cell Tumor / radiography. Gynecomastia / pathology. Gynecomastia / radiography. Humans. Infant. Infant, Newborn. Male. Nipples / abnormalities. Papilloma / diagnosis. Papilloma / pathology. Papilloma / radiography. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology. Phyllodes Tumor / radiography. Puberty. Puberty, Precocious / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448124.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


80. Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M: N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res; 2005 Apr 15;11(8):2986-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
  • PURPOSE: N(1),N(12)-diacetylspermine (DiAcSpm) in the urine of colorectal and breast cancer patients was examined to establish its usefulness as a novel diagnostic tool for detecting these cancers at clinically early stages.
  • EXPERIMENTAL DESIGN: Urine samples from 248 colon cancer patients and 83 breast cancer patients as well as 51 patients with benign gastrointestinal diseases treated in Tokyo Metropolitan Komagome Hospital during the period of August 1999 to January 2004 were collected.
  • DiAcSpm was elevated in 60% of tumor-node-metastasis cancer stage 0 + I patients, whereas only 10% (P < 0.0001) and 5% (P < 0.0001) of these patients were CEA- and CA19-9-positive, respectively.
  • The sensitivity of urinary DiAcSpm for 83 cases of breast cancer (60.2%) was higher than the sensitivities of CEA (37.3%, P = 0.0032) and CA15-3 (37.3%, P = 0.0032).
  • DiAcSpm was elevated in 28% of tumor-node-metastasis stage I + II patients, whereas only 3% (P = 0.0064) and 0% (P = 0.001) of these patients were CEA- and CA15-3-positive, respectively.
  • CONCLUSION: The observations indicate that urinary DiAcSpm is a more sensitive marker than CEA, CA19-9, and CA15-3 and that it can efficiently detect colorectal and breast cancers at early stages.
  • [MeSH-major] Biomarkers, Tumor. Breast Neoplasms / diagnosis. Colorectal Neoplasms / diagnosis. Spermine / analogs & derivatives
  • [MeSH-minor] Adult. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Mucin-1 / blood. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  •  go-up   go-down


81. El Idrissi F, Fadli A: [Erosive adenomatosis of the nipple]. J Gynecol Obstet Biol Reprod (Paris); 2005 Dec;34(8):813-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Adénomatose érosive du mamelon.
  • First rule out galactophoric carcinoma underlying all the erosions of the nipple or a breast tumor.
  • A 52-year-old woman consulted for a right breast tumor that had developing for more than four years due to a serious nipple flow.
  • Physical examination disclosed an ulcer tumor of the nipple and the superior quadrant of the areole.
  • Wide tumor resection was performed.
  • The histological analysis led to the diagnosis of erosive nipple adenomatosis.
  • Erosive adenomatosis of the nipple is a benign tumor which developing within the lactic nipple.
  • Clinically, the differential diagnosis is breast carcinoma, Paget disease and galactophoric dilatation.
  • Pathology is required for certain diagnosis.
  • Erosive adenomatosis of the nipple is very rare and should be suspected in patients with nipple erosions or a nipple tumor.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Nipples / pathology
  • [MeSH-minor] Biopsy, Needle. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged. Prognosis. Ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319774.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Manfrin E, Mariotto R, Remo A, Reghellin D, Falsirollo F, Dalfior D, Bricolo P, Piazzola E, Bonetti F: Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004). Cancer; 2009 Feb 1;115(3):499-507
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign breast lesions at risk of developing cancer--a challenging problem in breast cancer screening programs: five years' experience of the Breast Cancer Screening Program in Verona (1999-2004).
  • BACKGROUND: Cytology and core-needle biopsies are not always sufficient to exclude malignancy in benign breast lesions (BBL) that are at risk of developing cancer, and open biopsy often is mandatory.
  • In screening programs, open biopsies performed for lesions that are at risk of developing malignancy are considered benign.
  • The authors of this report evaluated the impact of the screen-detected BBL at risk of developing cancer that were counted in the quota of benign breast open biopsies in the Breast Cancer Screening Program of Verona.
  • METHODS: Benign open biopsies were subdivided into 4 groups according to their risk of developing cancer: Histo1, normal histology; Histo2, 'pure' BBL (fibroadenoma, fibrocystic disease, mastitis, adenosis); Histo3, BBL with a low risk of developing cancer (radial scar, papilloma, papillomatosis, phyllodes tumor, mucocele-like lesion); and Histo4, BBL with a high risk of developing cancer (atypical columnar cell hyperplasia, atypical ductal hyperplasia, atypical lobular hyperplasia).
  • RESULTS: Of 510 open biopsies, 83 biopsies were benign, and the ratio of benign to malignant biopsies was 1:5.
  • Histo1 was observed in 4.8% of all benign open biopsies, Histo2 was observed in 37.4%, Histo3 was observed in 31.3%, and Histo4 was observed 26.5%.
  • It is inappropriate to include BBL at risk of developing cancer in the overall benign open biopsy rate.
  • [MeSH-major] Biopsy / methods. Breast Diseases / complications. Breast Neoplasms / diagnosis


83. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


84. Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA: Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med; 2010 Oct 25;207(11):2421-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion.
  • In this study, we report that FLNa suppresses invasion of breast cancer cells and regulates focal adhesion (FA) turnover.
  • Two large progression tissue microarrays from breast cancer patients revealed a significant decrease of FLNa levels in tissues from invasive breast cancer compared with benign disease and in lymph node-positive compared with lymph node-negative breast cancer.
  • In breast cancer cells and orthotopic mouse breast cancer models, down-regulation of FLNa stimulated cancer cell migration, invasion, and metastasis formation.
  • These results document a regulation of FA dynamics by FLNa in breast cancer cells.


85. Scholtysek C, Krukiewicz AA, Alonso JL, Sharma KP, Sharma PC, Goldmann WH: Characterizing components of the Saw Palmetto Berry Extract (SPBE) on prostate cancer cell growth and traction. Biochem Biophys Res Commun; 2009 Feb 13;379(3):795-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Saw Palmetto Berry Extract (SPBE) is applied for prostate health and treatment of urinary tract infections, nonbacterial prostitis and Benign Prostatic Hyperplasia (BPH) in man.
  • An assumption is that SPBE affects tumor cell progression and migration in breast and prostate tissue.
  • In this work, DU-145 cells were used to demonstrate that SPBE and its sterol components, beta-sitosterol and stigmasterol, inhibit prostate cancer growth by increasing p53 protein expression and also inhibit carcinoma development by decreasing p21 and p27 protein expression.
  • The results show for the first time the potential of SPBE, beta-sitosterol and stigmasterol as potential anti-tumor agents.
  • [MeSH-major] Cell Proliferation / drug effects. Plant Extracts / pharmacology. Prostatic Neoplasms / metabolism. Sitosterols / pharmacology. Stigmasterol / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / antagonists & inhibitors. Cyclin-Dependent Kinase Inhibitor p27 / antagonists & inhibitors. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. STIGMASTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059205.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Permixon; 0 / Plant Extracts; 0 / Sitosterols; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 5LI01C78DD / gamma-sitosterol; 99WUK5D0Y8 / Stigmasterol
  •  go-up   go-down


86. Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA: Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer; 2008 Aug 5;99(3):491-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the quest for markers of expression and progression for prostate cancer (PCa), the majority of studies have focussed on molecular data exclusively from primary tumours.
  • Although expression in metastases is inferred, a lack of correlation with secondary tumours potentially limits their applicability diagnostically and therapeutically.
  • Those genes identified were verified on PCa cell lines and tumour samples from both primary and secondary tumours using real-time RT-PCR, western blotting and immunohistochemistry.
  • Claudin-4, coding for an integral membrane cell-junction protein, was the most significantly (P<0.00001) upregulated marker in both primary and metastatic tumour specimens compared with benign prostatic hyperplasia at both RNA and protein levels.
  • In primary tumours, claudin-4 was more highly expressed in lower grade (Gleason 6) lesions than in higher grade (Gleason >or=7) cancers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary
  • [MeSH-minor] Base Sequence. Blotting, Western. Cell Line, Tumor. Claudin-4. DNA Primers. Humans. Immunohistochemistry. Male. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate Suppl. 2000;9:4-14 [11056496.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):564-9 [17306334.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Histol Histopathol. 2001 Oct;16(4):1183-95 [11642738.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:169-84 [12095942.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):228-37 [12115574.001]
  • [Cites] Urology. 2003 Apr;61(4):736-41 [12670557.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Urol. 2004 Jan;171(1):187-91 [14665873.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6357-62 [14695135.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):903-14 [14982844.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):271-2 [15245824.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):535-46 [15762353.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):950-6 [15609297.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] J Urol. 2000 Aug;164(2):411-5 [10893598.001]
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Br J Dermatol. 2004 Aug;151(2):328-34 [15327539.001]
  • [Cites] Infect Immun. 1971 Aug;4(2):89-96 [4343403.001]
  • [Cites] Adv Cancer Res. 1976;23:23-89 [179291.001]
  • [Cites] Biochem Biophys Res Commun. 1979 Nov 28;91(2):629-36 [229852.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1732-6 [7523720.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):218-22 [8548767.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3629-34 [9288760.001]
  • [Cites] J Biol Chem. 1997 Oct 17;272(42):26652-8 [9334247.001]
  • [Cites] Prostate. 1998 Sep 15;37(1):19-29 [9721065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):511-6 [9892664.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24 [10379964.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3192-8 [10397265.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7378-85 [16103090.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):708-15 [16203278.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4549-52 [16651402.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):231-6 [16678055.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21433-44 [16714763.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):246-58 [16829686.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2000;(205):1-2 [11144889.001]
  • (PMID = 18648369.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / DNA Primers; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2527792
  •  go-up   go-down


87. Zanetti-Dällenbach RA, Schmid S, Wight E, Holzgreve W, Ladewing A, Hahn S, Zhong XY: Levels of circulating cell-free serum DNA in benign and malignant breast lesions. Int J Biol Markers; 2007 Apr-Jun;22(2):95-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of circulating cell-free serum DNA in benign and malignant breast lesions.
  • PURPOSES OF THE STUDY: We analyzed circulating cell-free DNA in the serum of patients with benign and malignant breast disease and in healthy individuals to determine its diagnostic value.
  • BASIC PROCEDURES: Serum samples were obtained from 50 healthy individuals, 33 patients with malignant breast disease and 32 patients with benign breast disease.
  • Tissue samples from patients with malignant and benign breast lesions were histopathologically examined.
  • MAIN FINDINGS: The mean levels of circulating cell-free DNA in serum samples were 41,149 genome equivalents (GE)/mL in patients with malignant disease, 30,826 GE/mL in patients with benign disease, and 13,267 GE/mL in healthy individuals.
  • Healthy individuals had significantly lower levels of cell-free DNA than patients with malignant or benign breast disease (p=0.001, p=0.031).
  • No significant difference was observed between malignant and benign disease.
  • There was a correlation between cell-free DNA levels and tumor size but not with other tumor characteristics.
  • PRINCIPAL CONCLUSION: Our results suggest that levels of circulating cell-free DNA in serum could have diagnostic value to discriminate between healthy individuals and patients with breast lesions but not between patients with malignant and benign breast lesions.
  • [MeSH-major] Breast Diseases / blood. Breast Neoplasms / blood. DNA / blood. DNA, Neoplasm / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549664.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


88. Zhao YS, Pang D, Wang F, Xue YW, Gao DN, Li H, Li K, Wang BY, Wang D, Li HY: Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):732-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC.
  • A matched case-control study was used to explore the association of CEA level in nipple aspiration fluids with breast disease.
  • Univariate and multivariate logistic regression were adopted to analyze the variables in relation to obtaining fluid and the association of its CEA levels and breast diseases.
  • Receiver operating characteristic curve was used to evaluate the value of CEA levels for the detection of breast disease.
  • CEA levels in nipple aspiration fluids of cancerous breasts were significantly higher than those from breasts with benign disease and healthy controls (ORadj, 5.39; P<0.01).
  • [MeSH-major] Biomarkers, Tumor / analysis. Body Fluids / chemistry. Breast Diseases / diagnosis. Carcinoembryonic Antigen / analysis. Nipples

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273481.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


89. Siddiqui MK, Jyoti, Singh S, Mehrotra PK, Singh K, Sarangi R: Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study. Environ Int; 2006 Jul;32(5):630-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of some trace elements concentration in blood, tumor free breast and tumor tissues of women with benign and malignant breast lesions: an Indian study.
  • Fifty women residing in and around New Delhi, India and identified to have benign (25 nos.) and malignant (25 nos.) breast lesions were studied for the first time to access the association between environmental exposure to lead and risk of breast cancer and to determine the potential of changes in trace elements concentration as a diagnostic marker and/or its etiological involvement in the disease.
  • Blood, tumor tissue and breast adipose tissue from tumor free area from each patient of the two groups, collected at the time of lumpectomy or mastectomy (only blood sample was collected from disease free control group), were analyzed to determine the concentration of Pb, Zn, Cu, Fe and Ca using Atomic Absorption Spectrometry.
  • Blood lead was significantly higher in malignant cases than in those of benign and control (p<0.05 each).
  • Lead level was also higher in tumor tissue when compared with their respective normal tumor free breast tissue, though non-significant, in both benign and malignant cases.
  • Interestingly, Zn, Fe, and Ca levels were higher in blood of malignant cases than in those of their benign counterparts.
  • Furthermore, these metals were also higher in tumor of malignant and benign cases as compared to normal tumor free breast tissue, many of them statistically significant (p<0.05/0.01/0.001).
  • However, Cu level was insignificantly lower in the blood and tumor tissue of malignant cases when compared with their benign counterparts while it was significantly higher (p<0.05) in tumor of benign cases when compared with those of their respective normal tumor free breast tissue.
  • There were statistically significant correlations between lead and trace element levels only in normal tumor free breast tissue of benign and malignant cases (r=0.41-0.73; p<0.05-0.001) but neither in blood nor tumor tissue of the two groups.
  • These results suggest that in the backdrop of existing experimental and epidemiological evidences exposure to lead may be one of the risk factors for breast lesions; though it warrants further investigation.
  • Further, modulation of trace elements level in both benign and malignant breast diseases patients may be of potential to be used as diagnostic marker of the disease process and its possible relationship etiologically.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Mammary Glands, Human / metabolism. Trace Elements / blood

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580070.001).
  • [ISSN] 0160-4120
  • [Journal-full-title] Environment international
  • [ISO-abbreviation] Environ Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Trace Elements
  •  go-up   go-down


90. El Tarhouny S, Seefeld M, Fan AX, Hahn S, Holzgreve W, Zhong XY: Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor. Cytokine; 2008 Oct;44(1):65-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
  • We wanted to find out whether VEGF, VEGFR1 or cfDNA is a biomarker for breast cancer.
  • METHODS: In this study, we used enzyme-linked immunosorbent assay (ELISA) to examine the levels of serum VEGF and VEGFR1 in 23 patients with benign tumors, 19 patients with breast cancer and 32 age-matched healthy females.
  • RESULTS: In terms of serum levels of either VEGF or its soluble receptors VEGFR1, we found no significant difference between healthy individuals and women with benign breast tumors and breast cancer.
  • However, there was a significant increase in circulating cell-free DNA in women with both benign and malignant breast tumors when compared with the corresponding healthy control group.
  • CONCLUSIONS: We can conclude that quantitative analysis of circulating cell-free DNA in serum may provide molecular biological understanding of breast tumors in women.
  • [MeSH-major] Breast Neoplasms / blood. DNA / blood. Vascular Endothelial Growth Factor A / blood. Vascular Endothelial Growth Factor Receptor-1 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691902.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 9007-49-2 / DNA; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1
  •  go-up   go-down


91. Otterbach F, Schmid KW: [Salivary gland-like tumors of the breast]. Pathologe; 2006 Sep;27(5):363-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salivary gland-like tumors of the breast].
  • [Transliterated title] Tumoren vom Speicheldrüsentyp in der Mamma.
  • A subset of rare benign and malignant breast tumors with and without myoepithelial differentiation are morphologically and histogenetically similar to salivary gland tumors, but may differ in incidence and clinical behavior.
  • The clinicopathological, immunohistochemical, molecular and prognostic features of ten salivary gland-like tumor entities of the breast are discussed and compared with their respective counterparts in the salivary glands.
  • [MeSH-major] Breast Neoplasms / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2003 Aug;120(2):161-7 [12931544.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Breast J. 2004 Sep-Oct;10(5):443-7 [15327500.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):795-801 [2161180.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):179-91 [14712223.001]
  • [Cites] Virchows Arch. 1996 Sep;429(1):69-74 [8865856.001]
  • [Cites] Virchows Arch. 2004 Jan;444(1):13-9 [14634807.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):545-7 [12101208.001]
  • [Cites] J Pathol. 2005 Aug;206(4):451-7 [15906273.001]
  • [Cites] ANZ J Surg. 2004 Dec;74(12):1135-7 [15574167.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e155-6 [12653606.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):248-58 [8434705.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):497-506 [12835294.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Jun 23;374(3):263-9 [196390.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):303-10 [9565338.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):119-22 [9504855.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1206-14 [1660850.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):74-81 [10963383.001]
  • [Cites] Semin Diagn Pathol. 2003 Nov;20(4):279-304 [14694981.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):351-8 [3578645.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):158-66 [10755607.001]
  • [Cites] Virchows Arch. 2002 May;440(5):536-42 [12021929.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):792-4 [2161179.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] BMC Cancer. 2005 Jul 28;5:92 [16050957.001]
  • [Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]
  • [Cites] Pathol Int. 1995 Jun;45(6):441-7 [7581936.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):347-53 [15725803.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1277-82 [15846389.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):285-8 [9769134.001]
  • [Cites] Cancer. 1991 May 1;67(9):2350-5 [2013041.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Histopathology. 2000 Mar;36(3):286-9 [10809602.001]
  • [Cites] Tunis Med. 2004 Mar;82(3):324-8 [15382470.001]
  • [Cites] J Pathol. 2002 Dec;198(4):487-94 [12434418.001]
  • [Cites] Virchows Arch. 2005 Feb;446(2):142-9 [15583933.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1045-53 [3022669.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(2):153-9 [8385380.001]
  • (PMID = 16896677.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Jung EM, Jungius KP, Rupp N, Gallegos M, Ritter G, Lenhart M, Clevert DA, Kubale R: Contrast enhanced harmonic ultrasound for differentiating breast tumors - first results. Clin Hemorheol Microcirc; 2005;33(2):109-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast enhanced harmonic ultrasound for differentiating breast tumors - first results.
  • PURPOSE: To investigate the extent to which indeterminate lesions of the breast can be differentiated in the early and late phase after bolus injection of the ultrasound contrast medium Optison.
  • MATERIALS AND METHODS: Fifty female patients (mean age: 49 years) with a altogether 53 preoperatively impalpable indeterminate breast tumors, 20 fibroadenomas and 33 carcinomas, were examined by B-mode imaging and contrast medium-enhanced ultrasound with power Doppler (three patients had multifocal carcinomas).
  • The tumors had a diameter of 5-15 mm (mean diameter: 9 mm).
  • A bolus of 0.5 ml Optison was injected intravenously and spreading of the contrast enhancement and washout in the tumors were followed for at least 20 minutes.
  • Maximum tumor size was measured and tumors vessels were evaluated in digital cine ultrasound sequences.
  • RESULTS: Without CM administration, 14 of 19 tumor lesions smaller than 10 mm could be distinguished better from the surrounding tissue with THI compared to fundamental B-mode imaging.
  • Both benign (17/20) and malignant (30/33) tumors exhibited increased tumor marginal vessels or intratumoral vessels in the early phase after CM injection.
  • A diffuse contrast medium accumulation was observed in the late phase (8-18 min, mean: 12 min) in 30 of 33 malignant tumors, but in none of the benign tumors.
  • The diagnostic confirmation for this late enhancement was there with 90% for the malignant tumors.
  • CONCLUSION: After intravenous bolus administration of Optison, breast carcinomas appear to have a prolonged diffuse enhancement of central tumor vasularity in the late phase compared to an earlier marginal vascularity of fibroadenomas.
  • [MeSH-major] Breast Neoplasms / ultrasonography. Contrast Media / standards
  • [MeSH-minor] Adult. Aged. Biopsy. Carcinoma / diagnosis. Carcinoma, Ductal. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Middle Aged. Neovascularization, Pathologic. Prospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151258.001).
  • [ISSN] 1386-0291
  • [Journal-full-title] Clinical hemorheology and microcirculation
  • [ISO-abbreviation] Clin. Hemorheol. Microcirc.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


93. Taira N, Ohsumi S, Aogi K, Maeba T, Kawamura S, Nishimura R, Takashima S: Nodular pseudoangiomatous stromal hyperplasia of mammary stroma in a case showing rapid tumor growth. Breast Cancer; 2005;12(4):331-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular pseudoangiomatous stromal hyperplasia of mammary stroma in a case showing rapid tumor growth.
  • Pseudoangiomatous stromal hyperplasia (PASH) is an uncommon benign breast disease that presents as a localized breast mass.
  • Breast tissue affected by PASH is characterized by a dense, collagenous proliferation of mammary stroma, forming interanastomosing capillary-like spaces.
  • The importance of this benign lesion lies in distinguishing it from low grade angiosarcoma.
  • We report a case of a 38-year-old woman who presented with a rapidly growing breast tumor.
  • She visited our hospital with a complaint of a painless right breast mass.
  • A fine-needle aspiration sample of the breast mass showed some clusters of epithelial cells with small papillary structures and many scattered stromal cells with naked nuclei.
  • Based on these findings, a provisional diagnosis of fibroadenoma was made and the patient was followed up.
  • Given the history of rapid growth of the mass, tumor excision was performed.
  • The excised tumor was well demarcated and had a smooth external surface.
  • Histologic examination revealed normal breast ducts and lobules, and specific proliferative epithelial changes were not seen.
  • The lobular and duct structure of the breast parenchyma were separated by an increased amount of stroma.
  • [MeSH-major] Breast / pathology. Breast Diseases / pathology. Breast Diseases / radiography. Breast Neoplasms / radiography
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Female. Humans. Hyperplasia. Stromal Cells / pathology


94. Barra Ade A, Gobbi H, de L Rezende CA, Gouvêa AP, de Lucena CE, Reis JH, Costa e Silva SZ: A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions. Diagn Cytopathol; 2008 Jan;36(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions.
  • The purpose of the study was to compare the accuracy of FNAC, CNB, and combined biopsy according to tumor size of suspicious breast lesions.
  • FNAC and CNB were performed in 264 patients with suspicious breast lesions from August, 1997 to August, 2002.
  • The lesions were divided in four groups according to the tumor size in the histopathology report: lesions smaller than 1 cm, between 1 and 2 cm, between 2 and 5 cm, and lesions greater than 5 cm.
  • The final surgical histopatology results identified 222 (84%) malignant cases and benign lesions summed 42 (16%).
  • The combination of FNAC and CNB can improve the diagnosis of suspicious breast lesions higher than 1 cm.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology
  • [MeSH-minor] Breast / pathology. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064684.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W: Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology; 2006 Jun;239(3):686-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study.
  • MATERIALS AND METHODS: After institutional review board approval and informed consent were obtained for this HIPAA-compliant study, breast MR spectroscopy was performed in patients with suspicious or biopsy-proved malignant lesions measuring 1 cm or larger at MR imaging.
  • Histologically, 31 (54%) of 57 lesions were malignant, and 26 (46%) were benign.
  • A choline peak was present in 34 of 57 lesions (including all cancers) and in three of 26 benign lesions, giving MR spectroscopy a sensitivity of 100% and a specificity of 88%.
  • CONCLUSION: Proton MR spectroscopy was successfully incorporated into breast MR imaging studies for lesions measuring 1 cm or larger.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / diagnosis. Choline / analysis. Magnetic Resonance Spectroscopy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) RSNA, 2006.
  • (PMID = 16603660.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


96. Ranade KJ, Nerurkar AV, Phulpagar MD, Shirsat NV: Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients. Indian J Med Sci; 2009 Nov;63(11):481-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients.
  • AIMS: In the present study, we analyzed the expression of apoptosis-regulating genes, viz., Survivin and mutant p53, in benign breast disease (fibroadenoma) and IDC patients.
  • CONCLUSIONS: Increased expression of Survivin and p53 in IDC patients and correlation with hormone receptors suggest that Survivin and p53 along with hormone receptors status are likely to contribute significantly to apoptosis resistance and may serve as therapeutic target that could increase the effectiveness of conventional breast cancer therapy.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics. Inhibitor of Apoptosis Proteins / genetics. Receptors, Estrogen / physiology. Receptors, Progesterone / physiology. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Apoptosis / drug effects. Biomarkers, Tumor. Female. Fibroadenoma / genetics. Fibroadenoma / immunology. Fibroadenoma / pathology. Humans. Immunohistochemistry. India. Middle Aged. Prognosis. Retrospective Studies. Statistics as Topic. Statistics, Nonparametric. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075549.001).
  • [ISSN] 1998-3654
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


97. Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A: CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):172-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms.
  • CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including breast myoepithelial cells.
  • However, its accuracy in other salivary tumors with myoepithelial component has yet to be analyzed.
  • We examined 72 salivary tumors with myoepithelial differentiation using immunohistochemical technique to detect CD10.
  • In neoplastic myoepithelial cells, CD10 expression was found in 25.71% of benign and 32.43% of malignant neoplasms.
  • When the different groups of tumors were compared, epithelial-myoepithelial carcinomas (EMEC) showed a stark contrast with the others (83.3% of cases with CD10 expression).
  • However, the gain of this protein is not a sensitive marker for detecting myoepithelial cells in the majority of the tumors, except for EMEC.
  • The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752720.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


98. Sandhya B, Babu V, Parthasarathy G, Kate V, Ananthakrishnan N, Krishnan R: Primary leiomyosarcoma of the breast: A case report and review of literature. Indian J Surg; 2010 Jul;72(Suppl 1):286-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the breast: A case report and review of literature.
  • Leiomyosarcomas of the breast are rare tumours.
  • We describe herein a case of primary leiomyosarcoma of the breast in a 54-year-old woman whose preoperative clinical and cytological findings indicated a benign breast tumour.
  • Histopathological examination of the mastectomy specimen suggested a diagnosis of leiomyosarcoma, which was subsequently confirmed by immunohistochemical analysis.
  • Primary leiomyosarcoma of the breast is very rare and is difficult to diagnose preoperatively as it needs immuno-histochemical staining.
  • It is necessary to excise the tumour with sufficient margins to prevent local recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1997;27(11):1082-5 [